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1.1 E QUINE HERPESVIRUS 1 (EHV-1): G E N E R A L
CHARACTERISTICS
Equine herpesvirus 1 (EHV-1) is a major pathogen of horses, responsible for
respiratory disorders, abortion, neonatal foal death and, less frequently, nervous system
disorders. EHV-1 infection is one of the most important causes of infectious abortion and,
therefore, brings about serious economic losses to the horse industry worldwide. The first
chapter of this review will describe the characteristics of EHV-1. In the following
chapters, the interaction of EHV-1 with its host cell as well as the interaction of the virus
with the naive and the immune horse will be discussed. An important feature in the
pathogenesis of an EHV-1 infection is the ability of the virus to be present inside
peripheral blood mononuclear cells (PBMC) and to spread to internal organs without
being recognized by the host’s immune system. The last chapter will review several
strategies that are exploited by herpesviruses to avoid elimination of infected PBMC by
the immune system.
1.1.1 History of EHV-1
In 1932, a filterable virus that caused abortion in mares was isolated by Dimock and
Edwards (Dimock and Edwards, 1933). The virus was first designated equine abortion
virus or equine rhinopneumonitis virus and, later, it was called “equine herpesvirus 1” or
“EHV-1”. Until 1981, 2 subtypes of this virus were described. “EHV-1 subtype 1” was
mainly associated with abortion and nervous system disorders and “EHV-1 subtype 2”
was mainly responsible for respiratory disorders. Restriction endonuclease and nucleotide
sequence analysis, however, indicated that “EHV-1 subtype 1” and “EHV-1 subtype 2”
were 2 distinct viruses (Sabine et al., 1981; Studdert et al., 1981; Turtinen et al., 1981)
and it was proposed to designate them EHV-1 and EHV-4, respectively (Studdert et al.,
1981). In 1988, this nomenclature was adopted by the Herpesvirus Study Group of the
International Committee on Taxonomy of Viruses.
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1.1.2 Classification
EHV-1 is a member of the family Herpesviridae. Herpesviridae are widely
disseminated in nature and infections are common in humans and most animal species.
All members of the family Herpesviridae share four biological properties (Roizman,
1991). Firstly, they contain a large deoxyribonucleic acid (DNA) genome that encodes a
variety of enzymes involved in nucleic acid metabolism and DNA synthesis. Secondly,
transcription of the herpesviral genome proceeds in a co-ordinately regulated cascade
manner. Thirdly, formation of the capsid occurs in the nucleus. Fourthly, all known
herpesviruses are able to establish a latent infection in their natural host.
Other biological characteristics such as host cell range, replication cycle, ability to
destroy cells and site of latency vary greatly among the different members of the
Herpesviridae. Based on these biological characteristics, the Herpesviridae have been
divided in three subfamilies: Alphaherpesvir inae , Betaherpesvirinae a n d
Gammaherpesvirinae (Table 1). More recently, the subfamilies have been subdivided
into genera based on DNA sequence homology, similarities in genome sequence
arrangement and relatedness of major viral proteins (Roizmann et al., 1992) (Table 1).
Table 1.  Characteristics of the subfamilies of Herpesviridae
Characteristics Herpesvirus subfamily
Alphaherpesvirinae Betaherpesvirinae Gammaherpesvirinae
Host cell range wide restricted restricted
Replication cycle short long long
Effect on host cell lysis cytomegaly transformation,
destruction
Site of latency primarily but not
exclusively in sensory
ganglia
secretory glands,
lymphoreticular cells,
kidneys
lymphoid tissues
Genera Simplexvirus
Varicellovirus
Mardivirus
Iltovirus
Cytomegalovirus
Muromegalovirus
Roseolovirus
Lymphocryptovirus
Rhadinovirus
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EHV-1 is classified into the genus Varicellovirus within the subfamily of
Alphaherpesvirinae. This classification is shared with bovine herpesvirus 1 (BoHV-1),
suid herpesvirus 1 (SuHV-1) and varicella-zoster virus (VZV) (McGeoch and Cook,
1994).
Beside EHV-1, other equine herpesviruses are known to infect the horse as well.
EHV-3, which causes equine coital exanthema, and EHV-4, which causes
rhinopneumonitis, are members of the Alphaherpesvirinae. EHV-2 and EHV-5 are
members of the Gammaherpesvirinae. Their role as pathogens for equines is still unclear.
EHV-6, EHV-7 and EHV-8 infect donkeys and have, therefore, been redesignated as
asinine herpesvirus 1, 2 and 3, respectively (Browning et al., 1988). Their pathogenic role
is comparable to EHV-3, EHV-2 and EHV-1, respectively. More recently, a new equine
herpesvirus was isolated, EHV-9 (Fukushi et al., 1997; Yanai et al., 1998). EHV-9 seems
to display only mild pathogenicity in horses (Taniguchi et al., 2000).
1.1.3 Virus structure and genome organization
The EHV-1 virion has the typical architecture of a herpesvirus. The different
components of the virion are schematically depicted in Figure 1.
Figure 1.  Schematic drawing of an EHV-1 virion (adapted from Favoreel, 1999)
gB gMgN
gE
gI
gC
gD
gH
gL
gK
DNA
envelope
icosahedral capsid
tegument
gp2
gG
Review of the literature 10
The innermost core of an EHV-1 virion contains a linear double-stranded DNA
genome. The core is enclosed in an icosahedral capsid of approximately 100 nm in
diameter composed of 162 capsomeres (12 pentameric and 150 hexameric). Each
capsomere has a cylindric shape with a channel running through the long axis. Core and
capsid form the nucleocapsid, which is surrounded by a layer of electron-dense material
known as the tegument. The tegument is enclosed by a lipoprotein envelope derived from
the host cell, in which different viral glycoproteins are embedded. Up till now, 12
different envelope glycoproteins have been described for EHV-1: glycoprotein (g) B, gC,
gD, gE, gG, gH, gI, gK, gL, gM, gN and gp2. Since the envelope glycoproteins play a
major role during the EHV-1 replication cycle, they will be discussed more thoroughly in
Chapter 1.2.2.
The genome of EHV-1 is organized as a linear double-stranded DNA molecule with
a base composition of 56 to 57 % G + C (Darlington and Rendall, 1963; Soehner et al.,
1965; Telford et al., 1992). The DNA molecule is approximately 150 kilobase pairs in
size and can be divided into 2 covalently linked components, L and S (Henry et al., 1981;
Whalley et al., 1981; Ruyechan et al., 1982; Telford et al., 1992) (Figure 2).
Figure 2.  Genomic organization of EHV-1
Abbreviations: TR, terminal repeat; IR, internal repeat; U, unique
The S or short component consists of a unique (US) sequence which is flanked by an
internal repeat (IRS) and a terminal repeat (TRS) sequence. The L or long region
comprises a unique (UL) sequence again flanked by an inverted repeat (IRL) and a
terminal repeat (TRL) sequence (Chowdhury et al., 1990; Yalamanchili and O’Callaghan,
1990). The complete genome sequence of EHV-1 has been elucidated in 1992 by Telford
et al. (1992). It contains 76 genes, all likely to encode proteins involved in the viral
replication cycle.
TRL IRL IRS TRS
UL US
L-component S-component
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1.2 REPLICATION OF EHV-1 IN THE CELL
1.2.1 EHV-1 replication cycle
The replication cycle of EHV-1 is divided into several steps, including entry of the
virus into the host cell, replication of the virus inside the host cell and release of the virus
from the host cell. A schematic representation of the various steps of the EHV-1
replication cycle is shown in Figure 3.
Figure 3.  The EHV-1 replication cycle (adapted from Favoreel, 1999)
The first step in the replication cycle of EHV-1 is the attachment of free virions to the cell surface (1). After
fusion of the viral envelope with the plasma membrane (2), the nucleocaspid is released into the cytoplasm
(3) and transported into the nucleus (4-5). DNA transcription (6) and replication (7) occur and RNA
molecules are transported to the cytoplasm and translated to proteins (8, 10). Capsid proteins are redirected
into the nucleus where encapsidation occurs (9). Viral envelope proteins are co-translationally transported
into the endoplasmatic reticulum (ER) (10) and subsequently incorporated into various cellular membranes,
while passing through the secretory pathway (11, 15-16). The nucleocapsid leaves the nucleus via budding
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through the inner leaflet of the nuclear membrane (12) and subsequent fusion with the outer leaflet of the
nuclear membrane (13). The nucleocapsid acquires its secondary envelope at the Golgi apparatus (14) and
then leaves the cell via vesicle-mediated exocytosis (15-17).
The replication cycle of EHV-1, and Alphaherpesvirinae in general, starts with the
attachment of free virions to the surface of a target cell. The first interaction between the
virion and the cell occurs via heparan-sulfate containing glycosaminoglycans present on
the cell surface and is relatively unstable (WuDunn and Spear, 1989; Mettenleiter et al.,
1990; Osterrieder, 1999). Subsequently, the interaction is converted to a stable binding
(Karger and Mettenleiter, 1993). Once stable binding of the virion to the cell is achieved,
the viral envelope and the plasma membrane will fuse and the nucleocapsid will be
released into the cytoplasm, a process called penetration (Spear, 1993). After release in
the cytoplasm, nucleocapsids are then transported to the nucleus. Here the DNA leaves
the capsid and enters the nucleus via nuclear pores (Roizman, 1991).
The transcription of viral DNA takes place inside the nucleus. As for all
herpesviruses, transcription of the EHV-1 genome is typically divided into distinct
phases. First, the immediate-early gene, called IR1, is expressed (Gray et al., 1987a,
1987b). IR1 is transcribed into a single mRNA (Harty et al., 1989, 1991), but multiple
immediate-early polypeptides are observed (Caughman et al., 1985, 1988; Robertson et
al., 1988). The major immediate-early polypeptide (IE1) functions as a regulatory protein
that activates expression of the next sets of genes, the early and late genes. Early genes
are expressed before DNA replication and encode proteins required for DNA replication
such as DNA polymerase and other enzymes such as thymidine kinase. The late genes are
expressed after the onset of DNA replication and mostly encode viral structural
components like capsid proteins and envelope glycoproteins.
Viral DNA replication, like transcription, takes place in the nucleus, resulting in
multiple copies of the EHV-1 genome. These newly synthesized DNA copies have to
assemble with the capsid proteins to form nucleocapsids. Upon translation in the
cytoplasm, capsid proteins enter the nucleus, most likely via a nuclear targeting signal,
after which capsid assembly and incorporation of viral DNA molecules occurs. Unlike
capsid proteins, viral envelope proteins are co-translationally transported into the
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endoplasmatic reticulum (ER) and are subsequently incorporated into various cellular
membranes while passing through the secretory pathway.
Although still not unanimously accepted, there is increasing evidence for a two-step
envelopment process during the maturation of Alphaherpesvirus virions, including EHV-
1 (Granzow et al., 2001; Mettenleiter, 2002). First, newly formed nucleocapsids bud
through the inner leaflet of the nuclear membrane, thereby acquiring a primary envelope.
For herpes simplex virus (HSV-1) (Roller et al., 2000) and SuHV-1 (Klupp et al., 2000)
it has been demonstrated that the UL34 protein is necessary for primary envelopment. For
EHV-1, it is not yet known which protein(s) is(are) involved. Primary envelopment is
followed by fusion of the primary envelope with the outer nuclear membrane, resulting in
the release of naked nucleocapsids into the cytoplasm. Inside the cytoplasm, final
tegumentation of the nucleocapsids occurs. A secondary envelopment takes place at the
trans-Golgi network. The nucleocapsids bud into lamellae and vesicles of the trans-Golgi
network, which contain newly synthesized and fully glycosylated viral envelope proteins,
and obtain their secondary envelope. The resulting complete virions then leave the cell
via vesicle-mediated exocytosis.
1.2.2 Role of viral envelope glycoproteins
EHV-1 encodes 12 different envelope glycoproteins which are involved in virus
attachment, penetration, egress and cell-to-cell spread. The function of each of the
glycoproteins will be briefly reviewed.
Glycoprotein B is one of the so-called essential envelope glycoproteins, meaning
that it is indispensable for virus replication. This glycoprotein is involved in the
penetration of the virus into the host cell and the cell-associated spread of the virus from
infected to uninfected neighbouring cells (Wellington et al., 1996a; Neubauer et al.,
1997).
Glycoprotein D is another essential envelope glycoprotein of EHV-1. It converts the
first unstable binding of the virion to the cell surface into a stable binding and is also
involved in cell-to-cell spread of the virus (Wellington et al., 1996b; Csellner et al.,
2000).
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Glycoprotein C is a non-essential envelope glycoprotein. Thus, a mutant EHV-1
lacking gC is still able to replicate in the host cell. The penetration of the mutant virus is,
however, delayed, most likely as a result of an impaired attachment, and the production
of virus progeny is greatly reduced (Osterrieder, 1999). Extracellular virus titres are 5- to
10-fold lower when the mutant virus is grown in continuous cell lines and 48- to 210-fold
lower when it is grown in primary equine cells. Osterrieder (1999) concluded that gC is
involved in the first unstable interaction of the virion with the glycosaminoglycans on the
surface of the target cell and in the process of egress.
The non-essential EHV-1 glycoproteins gE and gI (Flowers and O’Callaghan, 1992;
Matsumura et al., 1996, 1998) as well as gM (Osterrieder et al., 1996) contribute to the
cell-to-cell spread of the virus. Glycoprotein M is also involved in virus penetration
(Osterrieder et al., 1996). Processing of gM inside the infected cell depends on the
expression of gN (Rudolph et al., 2002).
Although expression of gG (Colle et al., 1992), gH (Robertson et al., 1991; Stokes et
al., 1996), gK (Zhao et al., 1992) and gL (Stokes et al., 1996) has been demonstrated in
infected cells, their functions in the replication cycle of EHV-1 are still unclear.
All genes encoding the above-mentioned glycoproteins have a sequence homologue
in other Alphaherpesviruses. In contrast, gp2 has only been described in the equine
Alphaherpesviruses EHV-1 and EHV-4. The functional significance of gp2 is not yet
fully known. Studies using a gp2-negative deletion mutant, demonstrated that gp2 is not
essential for virus growth in cell culture (Sun et al., 1994) and may be involved in entry
and in egress (Sun et al., 1996; Rudolph and Osterrieder, 2002).
The major functions of the EHV-1 envelope glycoproteins during the viral life cycle
are summarized in Table 2.
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Table 2.  Functions of the envelope glycoproteins of EHV-1
Glycoprotein (former name) Essential Function
gB (gp14) yes penetration, cell-to-cell spread
gC (gp13) no attachment, egress
gD (gp17/18 or gp60) yes penetration, cell-to-cell spread
gE (none) no cell-to-cell spread
gG (none) no unclear
gH (none) most likely unclear
gI (none) no cell-to-cell spread
gK (none) most likely unclear
gL (none) most likely unclear
gM (gp21/22a or gp45) no penetration, cell-to-cell spread
gN (none) no processing of gM
gp2 gp300 no unclear
1.2.3 Interaction of EHV-1 with the peripheral blood mononuclear cell (PBMC),
the natural carrier cell of the virus
Despite the fact that PBMC form the natural carrier cells for EHV-1 in the blood and
play a crucial role in the pathogenesis of an EHV-1 infection, studies on the interaction
between EHV-1 and equine PBMC are limited and date from the early 1980’s. The
identity of EHV-1-infected PBMC in vivo was addressed by Scott et al. in 1983. They
experimentally inoculated pony foals and collected PBMC as well as physically separated
subpopulations of T-lymphocytes, B-lymphocytes and monocytes to detect and quantify
the presence of virus within these cells. Infected PBMC were present between 2 and 14
days post inoculation, as determined by co-cultivation. The maximum number of infected
cells was observed at 4 days post inoculation (43.2 infected cells per 2 x 106 PBMC). At
all time points, T-lymphocytes were the predominant cell type that harboured virus. B-
lymphocytes and monocytes also harboured virus, but to a much lesser extent. The
maximum number of infected B-lymphocytes was 5-fold lower than that of infected T-
lymphocytes and the maximum number of infected monocytes was 8.5-fold lower.
Interestingly, when PBMC from infected ponies were co-cultivated in the presence of
pokeweed mitogen (PWM), virus was detected in a 10-fold higher number of PBMC,
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suggesting that mitogen in some way promotes viral replication in these cells (Scott et al.,
1983). Dutta and Myrup (1983) performed a similar study on PBMC isolated from EHV-
1-inoculated ponies and extended it with in vitro infection of PBMC. Their results
concerning in vivo-infected PBMC closely resembled those of Scott et al. (1983). In vitro
infected, non-stimulated PBMC gave a higher number of plaques than mitogen-
stimulated PBMC, in contrast to the results obtained in vivo. Until now, it has not been
elucidated how mitogens affect the replication of EHV-1 in equine PBMC.
To our knowledge, no studies have been performed on the replication kinetics of
EHV-1 in PBMC. In Chapter 3 of the present thesis, a closer look is taken at the
replication kinetics of EHV-1 in freshly isolated as well as in mitogen-stimulated equine
PBMC.
1.3 INTERACTION OF EHV-1 WITH THE HORSE
1.3.1 EHV-1 infection in the naive horse
EHV-1 causes a systemic infection in horses, which is characterized by mild
respiratory disorders, abortion, neonatal foal death and, less frequently, nervous system
disorders. A schematic drawing showing the events of an EHV-1 infection in the naive
horse is presented in Figure 4.
Figure 4.  Pathogenesis of an EHV-1 infection in the naive horse
1.
Respiratory infection
2.
Virus replication in
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4.
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Respiratory infection
Infection with EHV-1 occurs via contact with infectious secretions or via inhalation
of infectious aerosols. The primary site of replication is located in the epithelia of the
upper respiratory tract, including turbinates, pharynx, soft palatinum and trachea (Kydd et
al., 1994a). Subsequently, the virus penetrates the epithelial barrier to replicate in deeper
tissues of the respiratory tract and in the draining lymph nodes. From 12 hours post
infection, replication of EHV-1 can be demonstrated in mononuclear cells of the
retropharyngeal and submandibular lymph nodes (Patel et al., 1982; Kydd et al., 1994b)
and from 1 day after infection, viral replication is observed in the cranial and caudal parts
of the lungs (Kydd et al., 1994a). Replication in the respiratory tract of immunologically
naive horses can be extensive (Gibson et al., 1992a) and is accompanied by vasculitis,
thrombosis and development of herpetic lesions (Patel et al., 1982; Kydd et al., 1994a).
Nasal shedding of virus is observed from 1 day up till 7 to 14 days after infection (Gibson
et al., 1992a).
EHV-1 respiratory disease in naive horses is characterized by mild, transient clinical
signs, which are self-limiting within 9 days following infection (Gibson et al., 1992a).
Clinical signs include fever, anorexia, depression, swelling of the submandibular lymph
nodes, ocular discharge and profuse serous nasal discharge, which may become
mucopurulent. Virus replication in the lungs may cause bronchopneumonia. Secondary
bacterial infections enhance the severity of the disease.
Viremia
 Four to 6 days after respiratory infection, EHV-1-infected mononuclear cells enter
the blood, resulting in a cell-associated viremia. Carried by infected PBMC, EHV-1
spreads throughout the body and, finally, reaches internal organs such as the uterus and
the nervous system (Allen and Bryans, 1986). As mentioned in Chapter 1.2.3, T-
lymphocytes are the predominant PBMC that harbour virus during viremia (Scott et al.,
1983). Viremia generally lasts until 9 to 14 days post infection (Thein and Brown, 1988;
Gibson et al., 1992a), although McCartan et al. (1995) reported viremia lasting for 27
days.
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Abortion
When EHV-1-infected PBMC reach the pregnant uterus, this may result in abortion.
A key factor in the pathogenesis of EHV-1-induced abortion is the infection of
endothelial cells in the endometrium, resulting in vascular damage and subsequent
dissemination of the virus into the foetus (Jackson et al., 1977; Edington et al., 1991;
Smith et al., 1992, 1993; Smith and Borchers, 2001). Uterine endothelial cells become
infected by transfer of EHV-1 from infected PBMC. In vitro studies performed by Smith
et al. (2002), indicated that activation of adhesion molecules on endothelial cells and
leukocytes may be a key step in this transfer of virus. This indication was strengthened by
the finding that endothelial cells of the pregnant equine reproductive tract showed an
activated expression of adhesion molecules (Smith et al., 2001). Interestingly, viral
replication and vascular damage are more extensive in the late pregnant uterus (Smith et
al., 1992, 1993) than in the early pregnant uterus (Smith et al., 1996) and 95 % of EHV-
1-induced abortions occur in the last 4 months of gestation (Doll, 1952; Doll and Bryans,
1963). The reasons for the different susceptibility of early versus late pregnant uteri are
not well understood.
Different strains of EHV-1 display different levels of virulence in terms of their
ability to induce abortion in pregnant mares. Mumford et al. (1994) demonstrated that
experimental inoculation of mares in late gestation with EHV-1 strain Ab4/8 resulted in
abortion in 3 out of 5 mares (60 %). In contrast, EHV-1 strain V592 induced abortion in 1
out of 10 infected mares only (10 %). Later studies showed that the level of virulence was
associated with the degree of endotheliotropism of the respective EHV-1 strain (Smith et
al., 2000).
EHV-1-induced abortion typically occurs in the last trimester of pregnancy (7-11
months). Abortion may be preceded by mild respiratory disorders, but in most cases
primary replication passes unnoticed. The incubation period varies from as less as 6 days
(Gleeson and Coggins, 1980) to as much as 4 months (Mumford et al., 1987). EHV-1-
induced abortions mostly occur as single cases. Only occasionally, clusters of abortions
or “abortion storms” are seen. Expulsion of the foetus usually occurs suddenly and mares
that abort seldom show premonitory signs. Foetus and placenta are expelled in a fresh
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state, except for the rare abortions that occur before 6 months of gestation. In those early
abortions, foetuses show severe autolysis.
When a foetus becomes infected late in gestation, a living foal may be delivered.
Such infected foals are usually weak, depressed and die within 24 hours post partum.
Some foals appear normal at birth, but develop severe respiratory distress within 18 to 24
hours and succumb within 3 days.
Nervous system disorders
When EHV-1-infected PBMC reach the nervous system, neurological disorders may
be induced. Initially, it was postulated that immune complexes played a key role in the
pathogenesis of EHV-1-induced neurological disorders. This postulation was based on
the observations that recovery of virus from the central nervous system frequently failed
(Jackson et al., 1977; Platt et al., 1980) and that the occurrence of the neurological
disorders coincided with high levels of circulating virus-specific antibodies (Edington et
al., 1986). However, Edington et al. (1986) provided clear evidence that EHV-1 itself can
infect endothelial cells of the blood vessels of the nervous system and that this forms the
initial step in the induction of vascular lesions. The vasculair lesions, mainly comprising
of vasculitis and thrombosis, result in secondary hypoxic degeneration of adjacent neural
tissue and, subsequently, in nervous system disorders. It is assumed that infection of
endothelial cells in the nervous system occurs via transfer of virus from infected PBMC,
as in the pregnant uterus. All parts of the central nervous system may be affected by
EHV-1.
As observed for abortion, the different ability of EHV-1 strains to induce nervous
system disorders (Mumford et al., 1994) appears to be associated with their degree of
endotheliotropism (Smith et al., 2000). Whether EHV-1 isolates exist with a tropism for
endothelial cells specific for either the pregnant uterus or the nervous system remains
unclear.
The incubation period of EHV-1-induced neurological disorders is 6 to 8 days
(Jackson and Kendrick, 1971; Jackson et al., 1977). The disorders may be preceded by
fever, general malaise and/or respiratory disorders 1 to 2 weeks earlier. Horses of all ages
and breeds may be affected. Pregnancy or recent foaling appears to be predisposing
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(Greenwood and Simson, 1980; McCartan et al., 1995; Goehring and Sloet van
Oldruitenborgh-Oosterbaan, 2001). EHV-1-induced neurological disorders may be seen
in individual horses or in multiple horses during outbreaks. The onset of neurological
disease is usually acute. Clinical signs vary in severity from mild hind limb
incoordination to severe paralysis and quadriplegia. Additionally, distal limb oedema,
head tilt, oedema of the testes, paralysis of the tail, penis prolaps as well as faecal and/or
urinary incontinence may be observed. Horses that do not develop quadriplegia have a
good chance of recovery, although this may take several weeks. Horses that have been
unable to stand for 24 hours have a poor prognosis (van Maanen et al., 2001).
Affected foals may develop gastro-intestinal disorders, uveitis, hypopyon as well as
pneumonia and sudden death may occur (Patel et al., 1982; McCartan et al., 1995).
Latency
Similar to the other members of the family Herpesviridae, EHV-1 establishes a
latent infection and persists in the host following a primary infection. During latency, the
entire viral genome is present in infected cells, but only a limited part undergoes
transcription, giving rise to latency-associated transcripts. No infectious virus is produced
(Roizmann et al., 1992). Latent EHV-1 has been detected in the trigeminal ganglion
(Edington et al., 1994; Slater et al., 1994; Baxi et al., 1995), in lymphoid tissue draining
the respiratory tract (Welch et al., 1992; Edington et al., 1994; Slater et al., 1994) and in
peripheral blood leukocytes (Welch et al., 1992; Chesters et al., 1997; Smith et al., 1998;
Banbura et al., 2000). EHV-1 latency in peripheral blood leukocytes was predominantly
established in CD5+/CD8+ T-lymphocytes (Smith et al., 1998).
A latent EHV-1 infection has been demonstrated in approximately 60 to 80 % of a
randomly selected population of abatoir horses, indicating that it is a common feature in
horses (Edington et al., 1994; Smith et al., 1998).
Immune response to primary EHV-1 infection
In general, a herpesvirus infection results in a local immune response at the primary
site of replication as well as in a systemic immune response. Each comprises a humoral
and a cell-mediated component. Breathnach et al. (2001) characterized the local humoral
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immune response to primary EHV-1 infection. Six naive weanling foals were
experimentally infected and EHV-1-specific antibody responses were measured in nasal
wash samples using immunoglobulin (Ig) A, IgGa, IgGb, IgG(T) and IgM isotype-
specific monoclonal antibodies. All these antibody isotypes were demonstrable in the
nasal mucus following EHV-1 infection, with virus-specific IgA being the predominant
antibody isotype detected throughout the sampling period. EHV-1-specific IgGa and
IgGb were occasionally present in excess of IgA at 1 or 2 weeks post inoculation. These
high levels of IgG in respiratory secretions were most likely caused by the exudation of
serum antibody through the inflamed respiratory epithelium.
Up till now, the local cell-mediated immune response to primary EHV-1 infection
has not been examined.
A systemic humoral immune response to primary EHV-1 infection is detectable as
early as 5 or 6 days after inoculation. By then, IgM and IgG antibody titres start to
increase (Stokes et al., 1991; Chong and Duffus, 1992). IgM antibodies rise to peak titres
between day 9 and 18 and slowly decline afterwards. IgG antibody titres peak later (18-
28 days) and remain high for at least several months (Stokes et al., 1991; Gibson et al.,
1992b). When looking at the functionality of the evoked antibodies, it is shown that
virus-neutralizing (VN) antibodies are first detectable between 10 and 21 days after
primary infection of horses (Edington and Bridges, 1990; Stokes et al., 1991; Chong and
Duffus, 1992; Gibson et al., 1992b; Tewari et al., 1993). They reach a maximum between
33 and 60 days and remain high for at least several months (Chong and Duffus, 1992;
Gibson et al., 1992b; Tewari et al., 1993). Complement fixation (CF) antibodies start to
rise between 7 and 15 days post inoculation (Edington and Bridges, 1990; Gibson et al.,
1992b; Tewari et al., 1993), peak between 26 and 60 days post inoculation and decline
thereafter (Gibson et al., 1992b; Tewari et al., 1993).
Studies on the systemic cell-mediated immune response to primary EHV-1 infection
are rather restricted and only address the proliferative response of lymphocytes. This
response has been examined by incubating lymphocytes from primary infected horses
with EHV-1 antigens (virus-specific lymphocyte response) (Wilks and Coggins, 1976;
Thomson and Mumford, 1977; Dutta et al., 1980; Hannant et al., 1991; Chong and
Duffus, 1992) or with phytohemagglutinin (non-specific lymphocyte response) (Dutta et
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al., 1980; Bumgardner et al., 1982; Hannant et al., 1991) and by subsequent
determination of the uptake of 3H-thymidine. The studies provided evidence that
lymphocytes of primary infected horses display reactivity towards EHV-1 antigens. Most
authors also reported an increase in the non-specific lymphocyte proliferation, indicative
of a generalized activation of the lymphocyte responsiveness, except for Hannant et al.
(1991), who described a suppression of the non-specific lymphocyte proliferation
following EHV-1 infection. So far, no studies are available on the response of cytotoxic
T-lymphocyte (CTL) precursors (memory CTL) or on the response of CTL effectors
following a primary EHV-1 infection.
1.3.2 EHV-1 infection in the infection-immune horse
Horses may become re-infected as early as 2 months after primary infection (Gibson
et al., 1992a). Apparently, the protective potential of the local immunity resulting from an
EHV-1 infection is of short duration. Virus replication in the respiratory tract of
infection-immune horses is, however, restricted when compared to that in naive horses.
Gibson et al. (1992a) found a 10- to 100-fold reduction in nasal virus titres upon re-
infection of foals 2 months after primary infection. The duration of nasal viral shedding
as well as the severity of respiratory disease are also reduced upon re-infection and
depend on the time interval after which re-infection occurs. Re-infection within 103 days
after primary infection resulted in nasal virus shedding for a maximum of 2 days and no
clinical signs were apparent (Gibson et al., 1992a; Slater et al., 1993; Tewari et al.,
1993). When re-infection was performed at 5 (Edington et al., 1990) or 6 (van der
Meulen, unpublished results) months after primary infection, nasal viral shedding was
also observed for a maximum of 2 days and horses showed fever. Other studies on the
pathogenesis of an EHV-1 infection report nasal virus shedding lasting up to 5 - 9 days
after inoculation of infection-immune horses and describe the occurrence of mild
respiratory disease, comprising fever, anorexia and serous nasal discharge, between 1 to 5
days following inoculation (Gleeson and Coggins, 1980; Edington et al., 1991; Kydd et
al., 1994a; Mumford et al., 1994; Allen et al., 1995). However, these studies lack
information on the exact time point at which a prior EHV-1 infection had occurred.
23 Chapter 1
An important feature in the pathogenesis of an EHV-1 infection in immune horses is
that viremia may occur despite the presence of high levels of systemic EHV-1-specific
antibodies (Doll and Bryans, 1963; Gleeson and Coggins, 1980; Mumford et al., 1987)
and EHV-1-specific CTL precursors (O’Neill et al., 1999). Consequently, EHV-1 can
spread to internal organs and cause abortion or nervous system disorders even though
horses possess an active immunity. Re-infection with EHV-1 may result in viremia as
early as 6 months after prior exposure to EHV-1 (van der Meulen, unpublished results).
Infected PBMC may be present up to 9 - 13 days upon re-infection with EHV-1, which is
almost similar as observed for naive horses (Gleeson and Coggins, 1980; Edington et al.,
1991; Kydd et al., 1994a; Mumford et al., 1994; van der Meulen, unpublished results).
Up till now, it is unclear how EHV-1-infected PBMC are able to circumvent efficient
elimination by the host’s immune response. The studies presented in Chapter 4 of the
present thesis will treat some aspects of the inefficient elimination of EHV-1-infected
PBMC.
Nasal virus replication and viremia in infection-immune horses may also occur
following reactivation of latent EHV-1 (Edington et al., 1985; van Maanen et al., 2000).
Reactivation of latent virus may be induced by stress situations under field conditions
(Burrows and Goodridge, 1984; van Maanen et al., 2001) or by immunosuppression after
treatment with corticosteroids (Edington et al., 1985; Gibson et al., 1992a; Slater et al.,
1994). Reactivation of EHV-1 with corticosteroids resulted in nasal virus shedding for a
period of 7 to 10 days in 40 (Edington et al., 1985) to 100 % (Gibson et al., 1992a; Slater
et al., 1994) of the treated horses. Edington et al. (1985) and Gibson et al. (1992a) also
detected viremia in 63 and 100 % of the animals, respectively. Viremia lasted for 1 to 4
days. Even though latent EHV-1 could be demonstrated in a large number of randomly
selected horses (Edington et al., 1994; Smith et al., 1998), the incidence of reactivation of
latent EHV-1 and the importance of reactivation in the induction of clinical disease is
unclear.
Various studies addressed the immune response to EHV-1 in infection-immune
horses. Breathnach (2001) examined the local humoral immune response. Nasal wash
samples were collected at weekly intervals post inoculation and EHV-1-specific antibody
responses were measured. As observed for naive foals, EHV-1 infection of infection-
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immune horses mainly elicited IgA, which remained detectable till at least 26 weeks after
inoculation. High levels of IgG in respiratory secretions of some horses, present in excess
of IgA at 1 or 2 weeks post inoculation, were associated with the occurrence of
respiratory disease. The authors postulated that these high levels of IgG resulted from an
exudation of serum antibodies through the inflamed respiratory epithelium, as mentioned
for naive weanling foals. Horses that remained clinically normal upon inoculation
showed no excessive amounts of IgG in their respiratory secretions.
To study the local cell-mediated immune response, Breathnach (2001) collected
nasal-associated lymphoid tissue and local draining lymph nodes at 1 week post
inoculation and analyzed the response of CTL precursors, the response of CTL effectors
and the EHV-1-specific lymphoproliferative response indicative for T-helper cell activity.
CTL precursors and CTL effectors were elicited in all horses following EHV-1
inoculation, suggesting that prior EHV-1 infection had resulted in the establishment of
virus-specific memory CTL, which were now rapidly recalled. Furthermore, a
lymphoproliferative response was observed in the retropharyngeal lymph nodes. The
duration of the local cell-mediated immune response and its role in the protection against
challenge infection were not examined.
With regard to the systemic humoral immune response in infection-immune horses,
re-exposure to EHV-1 induces an anamnestic antibody response for both CF and VN
antibodies, which may be detected within 1 week post inoculation (Edington and Bridges,
1990; van der Meulen, personal observations).
With regard to the systemic cell-mediated immune response evoked upon re-
infection of immune horses, studies by Charan et al. (1997) and Hannant et al. (1999)
demonstrated a long-term suppression of the virus-specific as well as the non-specific
lymphocyte proliferation response. Immunosuppression correlated with a rise in
circulating activated transforming growth factor-b and could be reversed by an antiserum
to transforming growth factor-b  (Charan et al., 1997). Alveolar macrophages, bronchial
epithelium, lymphoid tissue and platelets were indicated as the potential sources of
activated transforming growth factor-b during EHV-1 infection (Chesters et al., 2000).
Allen et al. (1995) studied the presence and activity of EHV-1-specific CTL precursors in
PBMC from infection-immune horses. As mentioned for the local immune response, CTL
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precursors or memory CTL have been established as a result of a prior exposure to EHV-
1 and can rapidly differentiate and mature into CTL effectors which, in turn, will
eliminate infected target cells. For their study, Allen et al. (1995) experimentally infected
immune horses, collected their PBMC and restimulated the CTL precursors in vitro by
culture with live, cell-free EHV-1. Subsequently, cytotoxic activity of the restimulated
CTL precursors against EHV-1-infected target cells was assessed. EHV-1-specific CTL
precursors were detected as early as 1 week post infection, reached maximum levels after
2 to 3 weeks and remained detectable for at least 1 year after infection. The cytotoxic
activity was predominantly displayed by CD8+ T-lymphocytes and was restricted by
major histocompatibility complex (MHC) class I molecules. Siedek et al. (1999)
modified the assay of Allen et al. and restimulated PBMC in vitro using EHV-1-infected
dendritic cells instead of cell-free virus. In this manner, they showed that equine dendritic
cells, after being exposed to infectious virus, were able to restimulate cytotoxic activity of
EHV-1-specific CTL precursors, suggesting that they act as potent antigen-presenting
cells in vivo. O’Neill et al. (1999) demonstrated that ponies with higher frequencies of
MHC class I-restricted, EHV-1-specific CTL precursors were better protected against re-
infection with EHV-1, as evidenced by reduced or absent clinical signs, virus shedding
and viremia. Studies on the activity of EHV-1-specific CTL effectors in the blood of
infection-immune horses following re-exposure to EHV-1 are very limited. Breathnach
(2001) demonstrated the presence of circulating CTL effectors at 1 week after
experimental inoculation. The CTL effector response was, however, not examined at any
other time point post inoculation. Consequently, the course of the CTL effector response
during an EHV-1 infection is still unknown.
1.3.3 EHV-1 infection in the vaccination-immune horse
The purpose of vaccination against EHV-1 is 2-fold. First, vaccination has to
minimize virus replication in the respiratory tract upon subsequent exposure to virulent
EHV-1. In this manner, nasal shedding of virus will be reduced and respiratory disorders
may be prevented. Second, vaccination should prevent or at least minimize the
occurrence of viremia upon challenge infection, in view of protecting pregnant mares
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against subsequent abortion. The first purpose of vaccination seems to be fulfilled by the
available vaccines, as demonstrated by reduced nasal virus titres and absence of
respiratory disease upon challenge infection of vaccinated horses. In contrast, it seems
difficult to develop a vaccine that guarantees a full protection against viremia and,
consequently, against subsequent abortion upon challenge. In view of this, we will briefly
review several vaccination/challenge studies and field studies performed with vaccines
that have been developed for reducing the incidence of EHV-1-induced abortion.
Heldens et al. (2001) performed a vaccination/challenge study with Duvaxyn EHV1,
4
“, a whole virus inactivated and carbomer-adjuvanted vaccine containing EHV-1 and
EHV-4. Infection-immune pregnant mares were vaccinated three times and challenged 4
weeks later. A non-vaccinated group was included as a control. All mares, irrespective of
their vaccination status, became viremic upon challenge. Virus was isolated from PBMC
up to 14 days after challenge in the vaccinated mares, despite the presence of virus-
specific antibodies. In the non-vaccinated controls, infected PBMC were present up to 21
days post challenge. Interestingly, the incidence of EHV-1-induced abortion was clearly
reduced in the vaccinates. Only 1 out of 5 vaccinated mares aborted, whereas all 6 mares
aborted in the control group. This suggests that even though vaccination does not reduce
the number of viremic mares, it may reduce the number of infected PBMC per mare and,
subsequently, reduce the chance of their interaction with endothelial cells of the pregnant
uterus. Additionally, Heldens et al. (2001) examined the occurrence of viremia in
vaccinated and challenged naive foals. Only 3 out of 10 vaccinated foals became viremic
upon challenge, compared to 4 out of 5 non-vaccinated control foals. This significant
effect of Duvaxyn EHV1, 4“ in a group of naive foals seems little surprising, knowing that
the same vaccine was unable to reduce the number of viremic animals in a group of
infection-immune mares.
Studies on the ability of Pneumabort-K“, a whole virus inactivated and oil-
adjuvanted vaccine containing EHV-1, to protect against viremia and abortion are not
consistent. Upon introduction of vaccination in Kentucky in 1977, Bryans and Allen
(1982) demonstrated a reduction in the incidence of EHV-1-induced abortion from
6.8/1000 in 1977 to 1.8/1000 in 1980. However, in an experimental vaccination/challenge
study performed by Burrows et al. (1984), the incidence of EHV-1-induced abortion was
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similar for vaccinated mares (41 %) and non-vaccinated control mares (33 %), as was the
number of mares showing viremia (88 % and 77 %, respectively). Also the duration of
viremia was unaffected by vaccination. Virus was isolated from PBMC as long as 8 to 14
days after challenge, both in the vaccinated and in the non-vaccinated mares. When
yearlings and two-year-old ponies were vaccinated with Pneumabort K“ and
subsequently challenged, viremia was apparent in all animals upon challenge and lasted
for 4 to 10 days. In an experimental vaccination/challenge experiment, performed by
Bürki et al. (1990), 89% of the Pneumabort-K“-vaccinated animals became viremic upon
challenge and 50 % of vaccinated pregnant mares aborted. No comparison was made with
a non-vaccinated control group in this study.
Prevaccinol“ is a live-attenuated Rac-H virus vaccine developed by attenuating the
RacL11 strain of EHV-1 via serial passages on heterologous cells (Woyciechowska,
1960; Woyciechowska et al., 1980). The protective effects of Prevaccinol“ against EHV-
1-induced viremia and/or abortion have been tested in several field trials with variable
outcome. Von Benten and Petzoldt (1977) performed a six-year survey in German
thoroughbreds and reported that EHV-1 abortions occurred as frequently in vaccinated as
in non-vaccinated mares. On the other hand, introduction of the vaccine on 6 farms in
Poland resulted in a slight, but significant decrease in the number of foetal and neonatal
foal losses from 11.8 % to 8.9 % (Frymus et al., 1986). In a field trial performed over a
period of 6 years by Becker (1988), no cases of virus abortion were detected when mares
were vaccinated according to the manufacturer’s instructions. Bürki et al. (1990) carried
out an experimental vaccination/challenge study with Prevaccinol“. Vaccination followed
by subsequent challenge infection resulted in viremia in 8 out of 9 included horses.
However, in 4 of the 8 viremic animals, infected PBMC were only detected at 4 days post
challenge, suggesting that vaccination reduced the duration of viremia upon challenge.
Two out of 4 vaccinated pregnant mares aborted upon challenge. It could not be
concluded whether vaccination had reduced the abortion rate, since the study lacked a
control group of non-vaccinated pregnant mares.
Apart from the above-mentioned, commercially available vaccines, several
experimental vaccines have been designed for reducing the incidence of EHV-1-induced
viremia and/or abortion in horses. Dolby et al. (1995) immunized 5 yearling ponies with
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a vaccine containing the inactivated EHV-1 strain V592 in Freund’s complete adjuvant,
then revaccinated with inactivated V592 in Freund’s incomplete adjuvant and, finally,
challenged with virulent virus. Using this vaccination regime, cell-associated viremia was
prevented in all 5 animals upon challenge.
Another inactivated experimental vaccine was described by Cook et al. (1990). This
vaccine consisted of purified major EHV-1 envelope glycoproteins, instead of whole
virus, and was presented using immune stimulating complexes or ISCOMs. Hannant et
al. (1993) demonstrated that, although foals that were immunized with this vaccine all
developed viremia upon challenge infection, the duration and amount of viremia were
significantly reduced compared to non-vaccinated foals. On average, viremia lasted 11.5
days in the non-vaccinated foals and only 6 days in the vaccinated foals. The highest
amount of virus was detected at 8 days post challenge in both groups, but the mean tissue
culture infectious dose 50 (TCID50) recovered from 1 ml whole blood was 20 times lower
in the vaccinated animals than in the control animals.
Matsumura et al. (1996) examined the protective potential of an experimental
vaccine containing the live-attenuated KyA strain of EHV-1. This attenuated strain was
obtained by serial passages on heterologous cells (Randall and Lawson, 1962; Perdue et
al., 1974). Matsumura et al. (1996) immunized 6 weanling horses with attenuated KyA
and challenged them 4 weeks later. All 6 horses developed viremia upon challenge, but
the maximum duration of viremia was reduced when compared to challenge control
horses. Infected PBMC were isolated for only 3 to 6 days from the blood samples of the
vaccinated animals, while they were present for 16 to 19 days in the blood samples of the
challenge control animals.
An experimental vaccine based on a thymidine kinase-negative deletion mutant of
EHV-1 was described by Slater et al. (1993) and Tewari et al. (1993), whereas
Matsumura et al. (1998) described an experimental vaccine containing an EHV-1
deletion mutant lacking the genes encoding gE and gI. It was found that immunization of
foals with either the thymidine kinase-negative mutant (Slater et al., 1993; Tewari et al.,
1993) or the gE-/gI- mutant (Matsumura et al., 1998) did not prevent viremia upon
subsequent challenge. The effect of vaccination on the amount of viremia was examined
for the thymidine kinase-negative mutant only and it appeared that immunization with
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this mutant induced a 10-fold reduction in the number of infected PBMC (1/106) when
compared to non-immunized controls (1/105) (Slater et al., 1993). The effect of
vaccination on the duration of viremia was only addressed by Matsumura et al. (1998).
They found that immunization of foals with the gE-/gI- mutant had very little effect in
reducing the duration of viremia, with a mean duration of 8 to 10 days being observed in
the non-vaccinated controls and of 7 to 8 days in the vaccinates.
Many other alternative approaches for potential vaccination against EHV-1-induced
viremia and/or abortion have been explored, such as subunit vaccines comprising the
envelope glycoproteins gB, gC, gD, gH and/or gL, deletion mutants lacking genes
encoding gB, gC, gD, gM and/or gp2 and, finally, DNA vaccines based on the coding
region for gB, gC or gD. Since none of these “alternative” vaccines have actually been
tested for their ability to protect against EHV-1-induced viremia and abortion in horses,
they will not be further discussed in the present thesis.
 Taken all the data on vaccination together, it is clear that elimination of EHV-
infected PBMC by the vaccination-induced immunity is inefficient, as demonstrated by
the high incidence of viremia upon challenge infection. This is not unexpected knowing
that even the immune response induced by natural infection does not efficiently
eradicates EHV-1-infected PBMC, as previously discussed in Chapter 1.3.2.
In the next Chapter, we will take a closer look at the immune evasive strategies that
are exploited by herpesvirus-infected PBMC in order to avoid their elimination by the
different components of the host’s immune system.
1.4 IMMUNE EVASION STRATEGIES OF HERPESVIRUS-INFECTED
PBMC
When reviewing the literature on EHV-1 infection in horses, it attracts the attention
that EHV-1-infected PBMC are able to circulate in the host despite the presence of an
active immune response, either induced by natural infection (Chapter 1.3.2) or by
vaccination (Chapter 1.3.3). Apparently, elimination of circulating EHV-1-infected
Review of the literature 30
PBMC by the immune system is inefficient, allowing them to spread in the immune host
and, consequently, to reach the internal organs.
In general, recognition and subsequent destruction of herpesvirus-infected cells
involves three major immune effector mechanisms: the antibody-dependent lysis, the
MHC class I-dependent, CTL-mediated lysis and the natural killer (NK) cell-mediated
lysis. However, during evolution, herpesviruses have developed an impressive array of
strategies to minimize recognition and/or destruction by these immune effector
mechanisms. By doing so, they gain time to replicate in the host and spread to uninfected
hosts, thereby securing their own survival. This chapter will focus on immune evasion
strategies by which herpesvirus-infected PBMC can avoid elimination by the different
components of the immune system. Even though many other viral immune evasion
strategies may have been described, their relevance for herpesvirus-infected PBMC has
not (yet) been addressed.
1.4.1 Antibody-dependent lysis and evasion strategies of herpesvirus-infected
PBMC
Following infection of a cell with an enveloped virus, such as a herpesvirus, viral
proteins are synthesized and, subsequently, incorporated into cellular membranes while
being transported to the plasma membrane. When virus-specific antibodies bind to viral
glycoproteins present on the plasma membrane, the infected cell becomes recognizable
for the classical pathway of complement, for phagocytic cells and for NK cells, which are
the three major arms of the antibody-dependent immunity. Destruction via the classical
pathway of complement is then initiated by binding of complement component C1q to the
Fragment crystalizable (Fc) domain of the virus-specific antibodies at the plasma
membrane. This binding leads to the activation of the complement cascade, which finally
results in the assembly of the Membrane Attack Complex and in subsequent lysis of the
infected cell. Also NK cells and phagocytes bind to the Fc domain of the virus-specific
antibodies at the plasma membrane. This binding is mediated via Fc receptors present on
NK cells and phagocytes and results in lysis or phagocytosis of the infected cell,
respectively. An overview of the antibody-dependent cell lysis is shown in Figure 5.
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Figure 5.  Mechanism of antibody-dependent cell lysis of a virus-infected cell
Viral proteins are co-translationally transported into the ER lumen (1) and incorporated into transport
vesicles that bud off from the ER (2-3). Upon reaching the Golgi compartment, viral proteins undergo their
final glycosylation (4) and the resulting envelope glycoproteins are transported to the cell surface via
vesicle-budding from the Golgi (5). Here, the Fragment antigen binding (Fab) domain of virus-specific
antibodies binds to the viral glycoproteins (6). The Fc domain of the antibodies may then be recognized by
the C1q component of the classical complement pathway (7) or by the Fc receptors of phagocytes (8) and
NK cells (9), which leads to the destruction of the infected cell (10).
Several herpesviruses have developed strategies to avoid elimination of infected
PBMC by the antibody-dependent components of the immune system. First, SuHV-1-
infected monocytes are able to clear their cell surface from viral glycoproteins, a process
described as antibody-induced clearance of viral glycoproteins from the plasma
membrane (Favoreel et al., 1999a). In brief, addition of SuHV-1-specific antibodies to
SuHV-1-infected blood monocytes in vitro results in an aggregation of viral
glycoproteins on the plasma membrane and subsequent internalization of glycoprotein -
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antibody complexes, leaving the SuHV-1-infected monocytes with only few viral
glycoproteins on their surface. The viral proteins gB and gD are crucial for this
internalization process to occur (Favoreel et al., 1999a; Van de Walle et al., 2001;
Favoreel et al., 2002). Antibody-induced clearance of viral glycoproteins from the plasma
membrane renders SuHV-1-infected monocytes significantly less susceptible towards
antibody-dependent, complement-mediated lysis (Van de Walle et al., in press).
Activation of the three components of the antibody-dependent immune system relies
on their interaction with the Fc domain of virus-specific antibodies. Some members of the
herpesvirus family induce the surface expression of viral proteins that display Fc
receptor activity. By doing so, they capture the Fc domain of the virus-specific
antibodies, making it no longer available for interaction with C1q or with the Fc receptor
of NK cells and phagocytes. This disarming of virus-specific antibodies occurs via a
process called antibody bipolar bridging. Hereby, the antigen-specific Fab domain of an
antibody is bound to the respective viral protein, whereas the Fc domain of the same
antibody is bound to the viral Fc receptor (Frank and Friedman, 1989). The glycoprotein
complex gE/gI of SuHV-1 has been shown to possess Fc receptor activity (Favoreel et
al., 1999b) and its expression on the surface of infected blood monocytes helps to avoid
efficient antibody-dependent, complement-mediated lysis (Van de Walle et al., in press).
For VZV, the glycoprotein gE/gI complex also displays Fc receptor activity (Litwin et
al., 1992) and since Mainka et al. (1998) showed a clear surface expression of gE on
VZV-infected PBMC during viremia, it seems likely that gE/gI Fc receptor activity can
help VZV-infected PBMC to circumvent antibody-dependent lysis.
1.4.2 MHC class I-dependent, CTL-mediated lysis and evasion strategies of
herpesvirus-infected PBMC
Beside the antibody-dependent lysis, destruction of infected cells also involves MHC
class I-dependent, CTL-mediated lysis. When a cell becomes infected with a virus,
proteasomes present in the cytoplasm of the infected cell will process short peptides from
newly produced viral proteins. These viral peptides are translocated to the ER via
transporters associated with antigen presentation, where they are loaded onto MHC class
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I/b2-microglobulin heterodimers. The resulting complex then enters the secretory
pathway of the cell and is finally presented at the cell surface. CTL which specifically
recognize MHC class I associated with a foreign peptide, but not with self-antigens, then
induce the lysis of the infected cell. Figure 6 shows a schematic overview of the MHC
class I-dependent, CTL-mediated lysis.
Figure 6.  Mechanism of MHC class I-dependent, CTL-mediated lysis of a virus-
infected cell
Viral proteins are proteolytically degraded into peptides inside the proteasome (1). The peptides are then
transported into the lumen of the ER via transporters associated with antigen presentation (TAP) (2). In the
ER, peptides are loaded onto MHC class I molecules (3). The resulting complex is transported to the cell
surface via the secretory pathway (4-5). Once expressed at the cell surface, the infected cell becomes
recognizable for CTL (6), leading to its destruction (7).
Numerous mechanisms have been described by which herpesviruses can inhibit
expression of MHC class I - viral peptide complexes at the cell surface and, subsequently,
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inhibit recognition and destruction of the infected cell by CTL. They include inhibition of
peptide production and loading, inhibition of peptide transport to the ER, interference
with MHC class I processing and inhibition of MHC class I - viral peptide trafficking
through the cell. Up till now, only 2 of these mechanisms have been demonstrated in
herpesvirus-infected PBMC. Firstly, Epstein-Barr virus (EBV) is able to interfere with
peptide production and loading in PBMC. B-lymphocytes from individuals latently
infected with EBV express Epstein-Barr nuclear antigen 1 (EBNA-1) (Levitskaya et al.,
1995). It was found that EBNA-1 is resistant to degradation by proteasomes and,
consequently, its loading onto MHC class I molecules and its presentation to CTL are
inhibited. Since EBNA-1 is the only protein in B-lymphocytes detected during latent
infection, it is suggested that its resistance to degradation allows the latently infected B-
lymphocytes to persist without being noticed by CTL (Levitskaya et al., 1995). During
the lytic phase of an EBV infection in B-lymphocytes, the peptide loading is
compromised. EBV transcribes the BCRF-1 gene, which encodes a viral homologue of
human interleukin-10 (Zeidler et al., 1997). The viral interleukin-10 indirectly hampers
the transport of peptides into the ER by downregulating the expression of the transporter
associated with antigen presentation, TAP-1. The resulting reduction of MHC class I
molecules on the cell surface involves all B-lymphocytes and may, therefore, affect the
recognition of EBV-infected B-lymphocytes by CTL. Human cytomegalovirus (HCMV)
can also interfere with peptide loading (Gilbert et al., 1996). The virus encodes a viral
kinase, designated pp65, which phosphorylates the immediate-early antigen IE-1 of
HCMV. By doing so, the loading of IE-1 onto MHC class I molecules is blocked and,
consequently, the presentation of IE-1 to CTL is inhibited. Pp65 is frequently monitored
in the mononuclear cells from the blood of HCMV-infected humans (Greijer et al., 2001;
Lautenschlager et al., 2002), indicating that it may contribute to an inefficient recognition
of these cells by CTL.
Secondly, VZV interferes with MHC class I - viral peptide trafficking through the
cell. Abendroth and Arvin (2001) found a significant decrease in MHC class I expression
on the surface of VZV-infected T-lymphocytes during viremia in experimentally
inoculated mice, when compared to non-infected T-lymphocytes. Co-localization studies
demonstrated that MHC class I molecules maintained in the Golgi apparatus of the
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infected cells, instead of continuing their way up to the plasma membrane. The identity of
the viral gene(s) responsible for the retention of MHC class I molecules in the Golgi
apparatus remains to be determined.
Alternatively, SuHV-1-infected blood monocytes undergo a non-specific clearance
of MHC class I molecules from their cell surface (Favoreel et al., 1999a). As mentioned
in the previous chapter, SuHV-1-specific antibodies induce the internalization of viral
glycoproteins from the plasma membrane of SuHV-1-infected blood monocytes. It was
found that the internalization of viral glycoproteins was accompanied by a co-
internalization of MHC class I molecules (Favoreel et al., 1999a). Disappearance of
MHC class I molecules from the cell surface reduced the susceptibility of the SuHV-1-
infected monocytes to CTL activity, as demonstrated by comparing the percentage of
lysed monocytes infected with wild type SuHV-1 with the percentage of lysed monocytes
infected with a mutant virus unable to cause antibody-induced internalization  (Favoreel,
1999).
1.4.3 NK cell-mediated lysis and evasion strategies of herpesvirus-infected PBMC
The viral strategies used to reduce the expression of MHC class I molecules on the
surface of infected cells may be protective against CTL recognition and destruction;
however, they render the infected cells highly susceptible to another arm of the host’s
immune system: the NK cells. NK cells are constitutively present in the host and they
destroy any cell that lacks MHC class I expression on its surface. To secure their
existence, viruses thus developed strategies to avoid recognition by NK cells. One of the
best-studied strategies is the surface expression of a viral MHC class I homologue which
can bind to inhibitory receptors on NK cells and, consequently, prevent NK cell-mediated
lysis of the infected cell. Gene UL18  of HCMV encodes such an MHC class I
homologue, gpUL18, and transcripts of this gene have been clearly demonstrated in
PBMC of patients with HCMV viremia (Hassan-Walker et al., 1998, 2001). Glycoprotein
UL18 binds to the Leukocyte Immunoglobulin-like Receptor 1 on NK cells, resulting in a
reduced NK cell-mediated cytotoxicity (Reyburn et al., 1997; Cosman et al., 1999).
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Until now, it has not been elucidated how EHV-1-infected PBMC are able to avoid
elimination by the major immune effector mechanisms. The research presented in the
present thesis addresses some aspects of the inefficient elimination of EHV-1-infected
PBMC in vitro and in vivo.
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AIMS OF THE STUDY
Equine herpesvirus 1 (EHV-1) is recognized worldwide as a major pathogen of
horses, causing serious economic losses due to abortion, neonatal foal death and, less
frequently, nervous system disorders. Peripheral blood mononuclear cells (PBMC) play a
crucial role in the pathogenesis of an EHV-1 infection. During the viremic phase of the
infection, infected PBMC transport EHV-1 from the primary site of replication to the
target organs, such as the pregnant uterus and the nervous system. As already mentioned
in Chapter 1.2.3 of the present thesis, basic knowledge on the interaction of EHV-1 with
equine PBMC is rather scarce. The first aim of this thesis was to obtain more detailed
information on the kinetics of EHV-1 replication in freshly isolated PBMC and on the
identity of the infected PBMC in vitro. Since earlier studies indicated that mitogens may
promote viral replication in PBMC, we also wanted to investigate the replication kinetics
in mitogen-stimulated PBMC and, subsequently, to obtain better insights in the
mechanism(s) by which mitogen stimulation affects the susceptibility of PBMC to EHV-
1.
An important feature in the pathogenesis of an EHV-1 infection is the ability of
EHV-1 to cause viremia in the horse in the presence of an active immunity.
Consequently, EHV-1-induced abortion or nervous system disorders may occur in
infection-immune and vaccination-immune horses. Apparently, elimination of circulating
EHV-1-infected PBMC by the immune system is inefficient. For other herpesviruses,
several immune evasion strategies have been described that enable herpesvirus-infected
PBMC to circumvent recognition and/or destruction by the major immune effector
mechanisms. Up till now, no such strategies have been described for EHV-1. The second
aim of this thesis was to obtain some insights in how EHV-1-infected PBMC are able to
avoid efficient elimination by humoral and cellular components of the host’s immune
system. Studies were performed using in vitro infected PBMC as well as infected PBMC
isolated from experimentally inoculated ponies.
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3.1.1 Summary
In the present study, the outcome of an inoculation of equine peripheral blood
mononuclear cells (PBMC) with equine herpesvirus 1 (EHV-1) was studied in vitro.
Cytoplasmic and plasma membrane expression of viral antigens, intra- and extracellular
virus titres and plaque formation in co-culture were determined. EHV-1 replicated in
monocytes, although in a highly restricted way. Viral antigens were found in a maximum
number of 8.7 % of the monocytes at 12 hours post inoculation (h pi). The infection was
productive in 0.16 % of the monocytes. The virus yield was 100.7 tissue culture infectious
dose 50 (TCID50) per productive cell. In a population of resting lymphocytes, 0.9 % of the
cells were infected and less than 0.05 % produced infectious virus. The virus yield was
100.1 TCID50 per productive cell. After prestimulation with different mitogens, the number
of infected lymphocytes increased 4 to 12 times. The susceptible lymphocytes were T-
lymphocytes. None of the infected PBMC were B-lymphocytes. In mitogen-stimulated
lymphocytes, a clear expression of viral antigens was found on the plasma membrane. In
conclusion, it can be stated that in freshly isolated PBMC, monocytes are the most
important cell fraction in which EHV-1 replicates. After mitogen stimulation of the
PBMC, T-lymphocytes become more susceptible.
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3.1.2 Introduction
Equine herpesvirus 1 (EHV-1), a member of the Alphaherpesvirinae, is a major
pathogen of horses, responsible for respiratory disorders, abortion, neonatal foal disease
and neurological disorders. Starting from 4-6 days after EHV-1 infection, an extensive
cell-associated viremia is detected which lasts until 9-14 days after infection (Gibson et
al., 1992). T-lymphocytes seem to be the most susceptible of the peripheral blood
mononuclear cells (PBMC) (Scott et al., 1983). Viremia is associated with e.g. T-cell
lymphopaenia and appearance of blastic cells (McCulloch et al., 1993) and may occur in
the presence of virus-neutralizing antibodies (Doll and Bryans, 1963; Mumford et al.,
1987). Carried by infected PBMC, EHV-1 spreads to internal organs.
Information on the interaction between EHV-1 and PBMC is rather scarce. Scott et
al. (1983) demonstrated EHV-1 infection of leukocytes by co-cultivation from 2 to 14
days after experimental inoculation of ponies. Virus was not detected by co-cultivation of
disrupted leukocytes. After mitogen stimulation of the leukocytes in culture, infectious
virus was detected in a higher number of cells and was also found by co-cultivation of
disrupted leukocytes. Dutta and Myrup (1983) performed a similar study, but extended it
with in vitro infection of leukocytes. For in vivo-infected leukocytes they obtained similar
results as Scott et al. (1983). In vitro infected, non-stimulated leukocytes gave a higher
number of plaques than mitogen-stimulated leukocytes, in contrast to the results obtained
in vivo.
The main purpose of this study is to obtain more detailed information about the
replication of EHV-1 in freshly isolated, equine PBMC and to investigate the effect of
mitogen stimulation on the replication kinetics of EHV-1 in lymphocytes.
3.1.3 Materials and Methods
Separation of PBMC in monocytes, T-lymphocytes and B-lymphocytes
PBMC were isolated by density centrifugation of heparinized blood from adult,
infection-immune horses on Ficoll-Paque (Pharmacia Biotech AB, Uppsala, Sweden) and
afterwards separated in 2 subpopulations by plasma-mediated adhesion as described by
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Nauwynck and Pensaert (1994). In brief, polystyrene tissue culture dishes (Corning, New
York, U.S.) were coated with 20 % autologous plasma in RPMI during 1 hour at 37 °C.
Afterwards, the dishes were washed and PBMC were layered on the dishes for 1 hour at
37 °C. Adherent cells consisted predominantly of monocytes and non-adherent cells
consisted predominantly of lymphocytes. Remaining monocytes in the lymphocyte-
enriched population were removed by plastic adhesion during 1 hour at 37 °C.
Mitogen stimulation
PBMC and lymphocytes were stimulated by adding pokeweed mitogen (PWM),
concanavalin A (ConA), phytohemagglutinin (PHA) or ionomycin and phorbol dibutyrate
(IONO/PDB) (Sigma, Bornem, Belgium) to the medium. Medium was further
supplemented with 10 U/ml of heparin (Leo, Zaventem, Belgium). Cellular DNA analysis
was performed at different time points as described by Darzynkiewicz et al. (1984).
Briefly, cells were fixed in ice-cold ethanol (70 %) for 30 minutes, washed and stained
for 30 minutes at room temperature with a solution containing 10 mg/ml propidium
iodide, 0.1 % Triton X-100, 2 mM MgCl2, 0.1 M NaCl, 10 mM PIPES buffer and 20
U/ml Rnase A in distilled water. Cells were analyzed by flow cytometry. Optimal
stimulation was obtained after 48 hours of treatment with concentrations of 4 µg/ml for
PWM, ConA or PHA and 0.5 µM and 10 nM for IONO and PDB, respectively.
Virus and infection
The Belgian EHV-1-strain 97P70 was used throughout the study. The strain was
isolated from lungs of an aborted fetus in 1997 and was plaque-purified twice in equine
embryonic lung cells. The strain was identified as EHV-1 using the monoclonal antibody
13B2 (Yeargan et al., 1985). Virus stocks used for inoculation were at the 6th passage.
PBMC and subpopulations were inoculated at a multiplicity of infection of 10, either
directly following isolation and separation or after 48 hours of mitogen stimulation.
Mock-inoculated cells were included as a control. After 1 hour of incubation at 37 °C,
extracellular virus was removed by treating the cells with a citrate buffer of pH 3
(Mettenleiter, 1989). After 2 washing steps, cells were resuspended in leukocyte medium
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(RPMI 1640, 10 % fetal bovine serum, 0.05 mM 2-mercaptoethanol, 100 U/ml penicillin,
0.1 mg/ml streptomycin, 0.1 mg/ml kanamycin, 0.3 mg/ml glutamin, 1 % non-essential
amino acids 100x (GIBCO BRL, Life Technologies Inc., Gaithersburg, Maryland, USA),
1 mM sodium pyruvate) and incubated at 37 °C and 5 % CO2.
Cell viability was determined by flow cytometry using propidium iodide (1 µg/ml),
at 3 and 24 hours post inoculation (h pi).
Immunofluorescence stainings
To determine the composition of PBMC and subpopulations immediately after
isolation and separation, an immunofluorescence staining was performed using
monoclonal antibodies HB88A and DH59B (VMRD Inc., Pullman, U.S.) to stain T-
lymphocytes and monocytes, respectively (Tumas et al., 1994). A hyperimmune goat
serum against horse IgM (Kirkegaard and Perry Laboratories Inc., Gaithersburg, U.S.)
was used to stain B-lymphocytes. Cells were analyzed by flow cytometry (FACSCalibur,
Becton Dickinson, U.S.).
To determine the percentages of freshly isolated as well as mitogen-stimulated cells
expressing viral antigens in the cytoplasm, cells were collected at various time points pi,
as indicated in Figure 1 and Table 2. Subsequently, cells were smeared on microscopic
slides using a Cytospin 3 (Shandon), fixed with aceton during 20 minutes at -20 °C and
stained using polyclonal, protein A-purified and biotinylated rabbit anti-EHV-1
antibodies followed by streptavidine labeled with fluoresceine isothyocyanate (FITC).
Samples were analyzed by fluorescence microscopy (Leica DM RBE, Wetzlar,
Germany).
Expression of viral antigens on the plasma membrane was determined in a total
population of IONO/PDB-stimulated PBMC only. PBMC were collected at 48 h pi and
an indirect immunofluorescence staining was performed, using polyclonal, protein G-
purified and biotinylated horse anti-EHV-1 antibodies followed by streptavidine-FITC. A
non-inoculated sample was included as control. Cells were analyzed by flow cytometry.
The identity of IONO/PDB-stimulated and infected PBMC was determined after 1,
24, 48 and 72 h pi. First, PBMC were stained in suspension at 4 °C with the specific cell
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markers as described above. Then, PBMC were smeared on microscopic slides, fixed
with paraformaldehyde (4 %) and permeabilized with Triton X-100. Finally, intracellular
viral antigens were stained using polyclonal, protein G-purified and biotinylated horse
anti-EHV-1 antibodies followed by streptavidine-FITC.
Virus titration
To quantitate extracellular virus titres, medium was collected at various time points
pi, as indicated in Figure 1 and Table 2. Medium was then centrifuged at 390 x g and
titrated on rabbit kidney (RK13) cells. To quantitate intracellular virus titres, cells were
collected and freeze-thawed twice. The cell lysate was centrifuged and the supernatant
was titrated.
Co-cultivation
For co-cultivation, cells were collected at 1 h pi and seeded on RK13 monolayers.
The monolayers were overlaid with 0.94 % carboxymethylcellulose (Sigma, Bornem,
Belgium) in leukocyte medium and centrifuged at 750 x g for 30 minutes to sediment the
cells onto the monolayer. Duplicate preparations were made after disruption of PBMC by
ultrasonication. Monolayers were placed at 37 °C and 5 % CO2. After 7 days of
incubation, the number of plaques was counted. Additionally, the percentage of PBMC
expressing viral antigens in their cytoplasm was determined at 12 h pi by indirect
immunofluorescence staining as described above.
3.1.4 Results
Composition of freshly isolated, non-inoculated PBMC and subpopulations
In the total population of PBMC, the percentages of T-lymphocytes, B-lymphocytes
and monocytes were 54.3 ± 0.1 %, 24.4 ± 1.7 % and 9.0 ± 0.3 %, respectively. In the
non-adherent population, the percentages were 66.4 ± 5.7 %, 24.9 ± 8.7 % and 1.0 ± 0.6
%, respectively. In the adherent population, 79.1 ± 5.2 % of the cells were identified as
monocytes.
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Replication of EHV-1 in freshly isolated PBMC, monocytes and lymphocytes
The percentages of PBMC, monocytes and lymphocytes expressing viral antigens in
the cytoplasm are presented in Table 1.
Table 1.  Viral antigen expression in freshly isolated, EHV-1-inoculated PBMC
% EHV-1 antigen-positive cells at … h piSelected
PBMC
fraction
3 5 7 9 12 24
Total PBMC 0.5 ± 0.2 1.5 ± 0.8 2.1 ± 0.4 2.3 ± 0.1 2.3 ± 2.1 2.5 ± 2.4
Monocytes 0.3 ± 0.3 3.9 ± 2.1 6.6 ± 2.6 8.1 ± 3.8 8.7 ± 4.2 7.5 ± 4.4
T- and B-
lymphocytes
0 0.5 ± 0.2 0.6 ± 0.3 0.7 ± 0. 4 0.5 ± 0.3 0.9 ± 0.6
All data are expressed as the mean value of three experiments ± standard deviation.
h pi: hours post inoculation
Viral antigens appeared from 5 h pi. The number of infected monocytes and PBMC
peaked at 12 (8.7 ± 4.2 %) and 24 h pi (2.5 ± 2.4 %), respectively, whereas the
percentage of infected lymphocytes remained below 1 % (Table 1). Mock-infected cells
yielded negative data in each case.
Figure 1 shows the kinetics of intra- and extracellular virus titres in freshly isolated
PBMC, monocytes and lymphocytes following EHV-1 inoculation. In PBMC and
lymphocytes, intracellular virus titres started to increase at 5 and 7 h pi, respectively and
reached a maximum at 12 h p.i (Figure 1). In the enriched monocytes, intracellular titres
increased from 3 h pi and reached a maximum at 7 h pi (Figure 1). Extracellular titres
increased only in the PBMC from 9 h pi (Figure 1).
The total number of plaques per 104 cells as determined by co-cultivation was 11.2 ±
0.8 for PBMC, 15.7 ± 7.5 for monocytes and 3.8 ± 1.4 for lymphocytes. The percentage
of infected cells at 12 h pi as determined by immunofluorescence was 1.3 ± 0.6 % for
PBMC, 1.2 ± 0.3 % for monocytes and 0.7 ± 0.3 % for lymphocytes. It was calculated
that plaque formation was induced by 13.7 ± 8.3 % of the infected monocytes, 9.2 ± 2.8
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% of the infected PBMC and 5.3 ± 0.9 % of the infected lymphocytes. No plaques were
observed in the duplicate preparations.
Figure 1.  Replication kinetics of EHV-1 in freshly isolated PBMC and
subpopulations
(a) Intracellular virus titres for the total population of PBMC and for the enriched subpopulations of
monocytes and T- and B-lymphocytes. (b) Extracellular virus titres. The detection limit for these assays
was 1.5 log10 TCID50. All data are expressed as the mean value of three experiments ± standard deviation.
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Viability was always higher than 65 % and no differences were observed between
EHV-1-infected and mock-infected cells.
Replication of EHV-1 in mitogen-stimulated PBMC and lymphocytes
The percentages of viral antigen-positive cells in mitogen-stimulated, EHV-1-
inoculated lymphocytes as well as intra- and extracellular virus titres are shown in Table
2.
Table 2.  EHV-1 infection in a subpopulation of T- and B-lymphocytes stimulated
with different mitogens
EHV-1 antigen-positive
cells  at … h pi (%)
Intracellular virus titres at …
h pi (log10 TCID50 / 106 cells)
Extracellular virus titres at …
h pi (log10 TCID50 / 106 cells)
Mitogen*
1 12 24 1 12 24 1 12 24
None 0 0.5 ± 0.8 0.5 ± 0.3 ≤1.5 ± 0 1.8 ± 0.2 1.9 ± 0.3 ≤1.5 ± 0 1.6 ± 0.1 1.8 ± 0.2
ConA 0 1.0 ± 0.3 2.9 ± 1.5 ≤1.5 ± 0 1.9 ± 0.3 3.2 ± 0.4 1.6 ± 0.1 1.7 ± 0.2 2.4 ± 0.3
PHA 0 1.2 ± 0.2 2.2 ± 1.2 ≤1.5 ± 0 1.7 ± 0 2.3 ± 0.3 ≤1.5 ± 0 1.8 ± 0.4 1.9 ± 0.4
PWM 0 2.4 ± 1.0 4.5 ± 1.3 ≤1.5 ± 0 2.1 ± 0.2 3.1 ± 0.9 ≤1.5 ± 0 1.6 ± 0.1 2.6 ± 0.1
0 2.9 ± 1.3 6.0 ± 1.9 ≤1.5 ± 0 2.1 ± 0.4 3.2 ± 0.5 1.6 ± 0.1 2.2 ± 0.4 3.3 ± 0.3IONO/
         PDB
* stimulation for 48 hours
Abbreviations: ConA, concanavalin A; PHA, phytohaemagglutinin; PWM, pokeweed mitogen;
IONO/PDB, ionomycin and phorbol dibutyrate; h pi, hours post inoculation
All data are expressed as mean values of three experiments ± standard deviation.
For all mitogens used, the percentage of infected lymphocytes increased 4 to 12
times. PWM and IONO/PDB showed the largest effect. ConA-, PWM- and IONO/PDB-
stimulated lymphocytes showed an increase in intra- and extracellular virus titres, when
compared to non-stimulated lymphocytes (Table 2). PHA only induced a slight increase
in intracellular titres (Table 2).
When identification was performed in a total population of mitogen-stimulated,
EHV-1-inoculated PBMC, it was found that most of the infected cells were T-
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lymphocytes (0.9, 7.3 and 3.3 % of the PBMC at 24, 48 and 72 h pi, respectively for
experiment 1 and 0.5, 2.6 and 2.0 % of the PBMC respectively for experiment 2).
Infected monocytes were only detected at 48 h pi (0.5 % of the PBMC). None of the
infected cells were B-lymphocytes.
Study of the expression of viral antigens on the plasma membrane at 48 h pi,
revealed that approximately 8 % of the mitogen-stimulated, EHV-1-inoculated PBMC
showed plasma membrane expression of viral antigens.
3.1.5 Discussion
Our results show that in fresh, unstimulated equine PBMC, monocytes are the most
important cell fraction in which EHV-1 replicates. Other Alphaherpesviruses such as
bovine herpesvirus 1 (BoHV-1) (Rouse and Babiuk, 1975; Nyaga and McKercher, 1980),
suid herpesvirus 1 (SuHV-1) (Wang et al., 1988) and herpes simplex virus (HSV)
(Plaeger-Marshall and Smith, 1978; Mintz et al., 1980) also mainly replicate in
monocytes / macrophages. However, for EHV-1, replication in monocytes is clearly
restricted. Less than 10 % of the monocytes express viral antigens and only 0.16 %
induces plaques in co-culture. Lack of viral antigen expression in more than 90 % of the
monocytes indicates that an early block exists in the replication cycle of EHV-1.
Moreover, most of the infected monocytes do not produce detectable amounts of EHV-1,
which may be explained by a block at another level in the replication cycle. This finding
that several blocks exist, is in agreement with results obtained with other
Alphaherpesviruses in monocytes (Albers et al., 1989; Nauwynck and Pensaert, 1994).
Based upon the highest extracellular virus progeny titer (103.9 TCID50 per 106 inoculated
cells) and the percentage of virus producing monocytes (0.16 %), it is estimated that 100.7
TCID50 virus was formed per virus-producing cell, which demonstrates that even virus-
producing monocytes are not fully productive. This is in contrast with SuHV-1
(Nauwynck and Pensaert, 1994). 
Our results with regard to the susceptibility of lymphocytes to EHV-1 infection are
somewhat different from those obtained in vivo by Scott et al. (1983). They suggested
that EHV-1 was mainly T-lymphotropic in unstimulated PBMC. We found that most of
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the unstimulated lymphocytes were refractory to infection. Very low percentages of
infected lymphocytes were detected and less than 0.05 % produced infectious virus on
co-culture.
EHV-1 showed an increased replication in mitogen-stimulated lymphocytes, which
is consistent with the results of Scott et al. (1983). Mitogens mimic the initial signals,
required to initiate cell proliferation or to induce a state of competence (Terada et al.,
1991). The ability of T-lymphocytes to support viral replication following mitogen
stimulation has been recognized for other herpesviruses as well (Nyaga and McKercher,
1980; Teute et al., 1983; Wang et al., 1988). HSV has long been known to replicate more
efficiently in actively dividing than in growth-arrested cells. Recently, Schang et al.
(1998) found that olomoucine and roscovitine inhibit HSV replication. Both substances
exert an influence on the cell cycle by inhibiting certain cyclin-dependent kinases. The
authors suggested that one or more of these kinases, which are active during the cell cycle
from the late G1-phase onward, are required for HSV replication. For EHV-1 similar
specific cell cycle events may play a role in virus replication. 
Activation of T-lymphocytes may be an important pathogenetic feature during an
EHV-1 infection. McCulloch et al. (1993) demonstrated an increase in the percentage of
blastic cells up to 40 % in the blood circulation of horses from 4-8 days and on day 10
after experimental inoculation with EHV-1. This coincides with the viremic phase of an
EHV-1 infection. Blastic transformation of lymphocytes, in vitro induced by mitogens or
in vivo induced during an EHV-1 infection, most likely provides a signal for the virus to
start its replication. The factor(s) inducing the proliferation of lymphocytes in vivo during
an EHV-1 infection are not yet examined.
Scott et al. (1983) experimentally infected ponies and collected blood samples at
different time intervals after infection. Blastic transformation of lymphocytes may have
taken place during infection before culturing the cells in vitro, which may explain why
EHV-1 replication was found in T-lymphocytes even without mitogen stimulation. In our
experiments, PBMC were obtained from healthy horses and were infected in vitro. It is
plausible that almost no blastic transformation occurred before mitogens were added in
vitro. The very low percentage of infected cells that we detected in the unstimulated
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lymphocytes may represent a small fraction of lymphoblasts, present in the blood of
healthy horses.
We demonstrated a clear plasma membrane expression of EHV-1 antigens on
mitogen-stimulated PBMC. Such an expression makes infected cells recognizable for
antibodies. After binding of the antibodies to their respective antigens, anchored in the
plasma membrane, cell lysis occurs by the activation of complement or phagocytes.
However, EHV-1-induced viremia occurs in the presence of virus-neutralizing antibodies
(Doll and Bryans, 1963; Mumford et al., 1987). How EHV-1-infected PBMC escape
from elimination by the host’s immunity is unknown and will be examined in the future.
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3.2.1 Summary
In the present study, equine herpesvirus 1 (EHV-1)-infected cells were identified in
ionomycin/phorbol dibutyrate (IONO/PDB)-stimulated peripheral blood mononuclear
cells (PBMC) and the mechanism by which stimulation increases the percentage of
infected cells was examined. In the population of viral antigen-positive PBMC, 38.4 ± 4.5
% were CD5+ T-lymphocytes (18.1 ± 3.2 % CD4+; 13.6 ± 1.8 % CD8+), 18.1 ± 5.4 %
were B-lymphocytes, 8.5 ± 3.9 % were monocytes and 35 % remained unidentified. The
role of the cell cycle in the increased susceptibility to EHV-1 upon stimulation was
examined by stimulating PBMC during 0, 12, 24 and 36 hours prior to inoculation. A
high correlation was found between the increase of cells in the S- (r = 0.974) and G2/M-
phase (r = 0.927) at the moment of inoculation and the increase of infected cells at 12
hours post inoculation (h pi). This suggests that a specific stage of the S-phase or S- and
G2/M-phase facilitates viral replication. At 24 h pi, lower correlations were found,
suggesting that other effects are involved. From 12 hours after addition of IONO/PDB,
formation of clusters of PBMC became manifest. It was examined if close intercellular
contacts in these clusters facilitated cell-to-cell transmission of EHV-1. Between 8 and 17
h pi, the percentage of clusters containing adjacent infected cells increased from 1.6 to
13.4 % and the maximal number of adjacent infected cells increased from 2 to 4.
Confocal microscopy visualized close intercellular contacts between adjacent infected
cells. It can be concluded that mitogen stimulation favours EHV-1 infection of PBMC (i)
by initiating specific cell cycle events and (ii) by inducing formation of clusters, thereby
facilitating transmission of virus between cells.
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3.2.2 Introduction
Equine herpesvirus 1 (EHV-1), a member of the Alphaherpesvirinae, is an important
pathogen of horses causing abortion, neonatal foal death, nervous system disorders and,
less frequently, respiratory disorders. An extensive cell-associated viremia during EHV-1
infection enables the virus to reach internal organs, even in the presence of virus-
neutralizing antibodies (Doll and Bryans, 1963; Mumford et al., 1987). During viremia,
the virus is carried by peripheral blood mononuclear cells (PBMC), mainly by
lymphocytes and to a lesser extent by monocytes, as described by Scott et al. (1983).
Somewhat different from these results obtained in vivo by Scott et al. (1983), we
found during in vitro studies that the majority of the EHV-1-infected equine PBMC are
monocytes, whereas most of the lymphocytes are refractory to infection (van der Meulen
et al., 2000). However, mitogen stimulation of PBMC prior to EHV-1 infection increases
the percentage of infected T-lymphocytes (van der Meulen et al., 2000). The identity of
the EHV-1-infected subtypes of mitogen-stimulated T-lymphocytes has not been
determined so far.
The finding that mitogen stimulation increases the number of infected T-
lymphocytes led to the hypothesis that EHV-1 replication in T-lymphocytes might benefit
from a specific phase of the cell cycle, induced by mitogen stimulation. Cell cycle-
dependent replication has already been demonstrated for several herpesviruses. For
example, herpes simplex virus (HSV) needs one or more cyclin-dependent kinases active
from late G1 onward and required for cellular progression into the S-phase, for the
accumulation of HSV transcripts, viral DNA replication and production of infectious
virus (Schang et al., 1998; Schang et al., 1999; Schang et al., 2000). Cyclin-dependent
kinases are also required for the replication of human cytomegalovirus (HCMV)
(Bresnahan et al., 1997). An effect of the cell cycle on the replication of EHV has already
been described by Lawrence (1971) in a human carcinoma cell line. He showed that
synthesis of EHV DNA takes place, only when the cells are in or just entering the S-
phase of the cell cycle. McCulloch et al. (1993) demonstrated an increase in the
percentage of blastic cells of up to 40 % in the blood circulation of experimentally
inoculated horses during a time period coinciding with the viremic phase of an EHV-1
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infection. Cell cycle-dependent replication of EHV-1 may be an important pathogenic
feature during an infection in vivo.
The main purpose of this study is to identify the EHV-1-infected subtype(s) of
mitogen-stimulated PBMC in vitro and to obtain better insights in the mechanism(s) by
which mitogen stimulation affects the course of an EHV-1 infection.
3.2.3 Materials and methods
PBMC
Blood samples were obtained from infection-immune horses by jugular venipuncture
and collected on heparin (Leo, Zaventem, Belgium). PBMC were then isolated by density
centrifugation on Ficoll-Paque (Pharmacia Biotech AB, Uppsala, Sweden). Cells were
washed three times with phosphate-buffered saline and resuspended in medium (RPMI
1640, 10 % fetal bovine serum, 0.05 mM 2-mercaptoethanol, 100 U/ml penicillin, 0.1
mg/ml streptomycin, 0.1 mg/ml kanamycin, 0.3 mg/ml glutamin, 1 % non-essential
amino-acids 100x (GibcoBRL), 1 mM sodium pyruvate).
Virus and in vitro infection
The Belgian EHV-1 strain 97P70 was used throughout all experiments (van der
Meulen et al., 2000). Virus used for inoculation was at the 5th passage on equine
embryonic lung cells and 1 subsequent passage on rabbit kidney (RK13) cells.
PBMC were infected at a multiplicity of infection of 10. After 1 hour of incubation
at 37 °C, the cells were washed thoroughly with RPMI and cultured in medium
supplemented with 10 U/ml heparin (Leo, Zaventem, Belgium) and with or without
addition of mitogens.
Mitogen stimulation
In a previous study, we have demonstrated that the highest number of EHV-1
antigen-positive PBMC was obtained after stimulation with a combination of the phorbol
ester, phorbol 12,13-dibutyrate (PDB), and the calcium ionophore, ionomycin (IONO)
(van der Meulen et al., 2000). Therefore, IONO and PDB were used throughout the
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experiments in the current study. PBMC were stimulated with 0.5 mM of IONO and 10
nM of PDB (Sigma, Bornem, Belgium) in medium as decribed earlier. Mitogen
stimulation was performed before or during EHV-1 infection, dependent on the
experiment.
Detection of viral antigen-positive PBMC
The percentage of EHV-1 antigen-positive cells was determined by indirect
immunofluorescence staining on acetone-fixed cell smears. Cells were incubated during 1
hour at 37 °C, first with mouse polyclonal antibodies against EHV-1 and, after 3 washing
steps in PBS, with goat anti-mouse antibodies labeled with fluoresceine isothyocyanate
(FITC). Samples were analyzed with a Leica DM BRE fluorescence microscope (Leica
Microsystems Holdings GmbH, Wetzlar, Germany). At least 200 cells were counted for
each sample.
Cell cycle analysis
Cells were fixed in ice-cold ethanol (70 %) during 30 minutes, washed with
phosphate-buffered saline and stained during 30 minutes at room temperature with a
solution containing 10 mg/ml propidium iodide, 0.1 % Triton X-100, 2 mM MgCl2, 0.1 M
NaCl, 10 mM Pipes buffer and 20 units/ml RNAse A in distilled water. The cells were
analyzed by flow cytometry using a Becton-Dickinson FACSCalibur and BD Cellquest
software (Becton-Dickinson, San Jose, CA, USA). The following parameters were stored
for further analysis: FSC, SSC, FL2-W and FL2-A. Gates were placed, based on FSC and
SSC profiles, to include viable cells only. At least 5000 cells were analyzed for each
sample.
Identification of EHV-1-infected, mitogen-stimulated PBMC
A double immunofluorescence staining was performed in 2 steps. First, the cells
were fixed in paraformaldehyde (3 %), washed with phosphate-buffered saline and
incubated during 1 hour with one of the monoclonal antibodies HT23A (anti-equine
CD5), HB61A (anti-equine CD4), 73/6.9.1. (anti-equine CD8) or DH59B (equine
monocyte marker) (VMRD, Pullman, WA, USA). Then, an FITC-conjugated goat anti-
69 Chapter 3
mouse antibody was added for 1 hour. To stain B-lymphocytes, an FITC-labeled goat
anti-horse IgM antibody (Kirkegaard and Perry Laboratories Inc., Gaithersburg, U.S.)
was used. After the first step, cells were washed in phosphate-buffered saline and
permeabilized with saponin (0.1 %). Then, the cells were incubated during 1 hour with
protein G-purified and biotinylated horse antibodies raised against EHV-1 and finally
with phycoerythrin-labeled streptavidin (Molecular Probes, Eugene, Oregon, USA). An
irrelevant monoclonal antibody 41D3 against a putative receptor for a porcine arterivirus
(Duan et al., 1998) as well as a non-infected sample were included as controls.
   Staining was performed either in suspension or within the recipient of cultivation.
For cells in suspension, all manipulations were performed at 4 °C. Samples were
analyzed by flow cytometry. Four parameters were stored for further analysis: FSC, SSC,
FL1 and FL2. Gates were placed, based on FSC and SSC profiles, to include viable cells
only. At least 10000 cells were analyzed for each sample. Within the recipient of
cultivation, all manipulations during the staining were performed at room temperature.
Cells were analyzed within their recipient with a Leica DM IL inverted fluorescence
microscope (Leica Microsystems Holdings GmbH, Wetzlar, Germany). At least 100 cells
or cell groups were counted for each sample. Additionally, cells were analyzed with a
Bio-Rad Radiance 2000 confocal laser scanning system (Bio-Rad House, Hertfordshire,
UK) linked to a Nikon Diaphot 300 microscope (Nikon Corporation, Tokyo, Japan).
3.2.4 Results
Identification of EHV-1-infected, IONO/PDB-stimulated PBMC by flow cytometry
PBMC were simultaneously stimulated and infected. Cells were collected at 48
hours post inoculation (h pi) and a double immunofluorescence staining was performed.
The percentage of the different cell types within the total population of PBMC and within
the population of EHV-1 antigen-positive PBMC are shown in Table 1.
The total population of PBMC consisted mainly of CD5+ T-lymphocytes (including
CD4+ and CD8+ T-lymphocytes), followed by B-lymphocytes. Monocytes formed the
smallest fraction of the PBMC. With the markers used in this experiment, 36.9 % of the
PBMC could not be identified.
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Most of the EHV-1 antigen-positive cells were CD5+ T-lymphocytes, followed by B-
lymphocytes. The minority of the EHV-1 antigen-positive cells were monocytes. Thirty-
five percent of the infected cells could not be identified. The composition of EHV-1-
infected PBMC reflected well the composition of the total population of PBMC.
Table 1.  Identification of the EHV-1-infected cells in IONO/PDB-stimulated
PBMC*
Percentage of cells identified as …
CD5+ T-lymphocytes B-lymphocytes Monocytes Unidentified†
Cell population total CD4+ CD8+
Total population of PBMC 46.2 ± 5.8 27.6 ± 3.6 10.6 ± 2.1 12.8 ± 2.2 4.1 ± 2.0 36.9
EHV-1-infected PBMC 38.4 ± 4.5 18.1 ± 3.2 13.6 ± 1.8 18.1 ± 5.4 8.5 ± 3.9 35
*: PBMC were simultaneously stimulated and infected, cells were collected at 48 h pi
†: 100 - (% CD5+ T-lymphocytes + % B-lymphocytes + % monocytes)
All data are expressed as the mean value of at least three experiments ± s.d.
Replication of EHV-1 in PBMC stimulated with IONO/PDB during different time periods
prior to inoculation
PBMC were stimulated for 0, 12, 24 or 36 hours and subsequently infected.
Stimulation was continued after inoculation. Non-stimulated PBMC were included as a
control. Cells were collected at 0, 12 and 24 h pi. Table 2 shows the distribution of cells
in the different stages of the cell cycle (G0/G1, S, G2/M) at the time point of inoculation
with EHV-1 and the percentage of EHV-1 antigen-positive cells at different time points
after inoculation for PBMC of three different infection-immune horses.
Based on the results of the 5 experiments, the mean percentage of PBMC in the
G0/G1-phase of the cell cycle decreased from 98.2 ± 1.0 % before stimulation to 93.3 ±
1.3 % after 36 hours of stimulation. The mean percentage of PBMC in the S- and G2/M-
phase increased from 1.5 ± 1.2 % and 0.4 ± 0.1 %, respectively before stimulation to 5.7
± 0.8 % and 1.1 ± 0.5 %, respectively after 36 hours of stimulation.
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Table 2.  Replication of EHV-1 in PBMC stimulated with IONO/PDB during
different time periods prior to inoculation
Stimulation with IONO/PDB Cell cycle distribution at
EHV-1 inoculation (%)
EHV-1 antigen-positive
cells  at … h pi (%)
Horse
number
prior to EHV-1
inoculation (hours)
after EHV-1
inoculation
G0/G1 S G2/M 0 12 24
1* No (0) No 98.2 ± 1.4 1.6 ± 1.6 0.3 ± 0 0 2.5 ± 2.8 1.4 ± 1.5
No (0) Yes 98.2 ± 1.4 1.6 ± 1.6 0.3 ± 0 0 3.8 ± 3.1 3.5 ± 3.2
Yes (12) Yes 96.9 ± 1.0 2.5 ± 0.5 0.7 ± 0.4 0 5.4 ± 3.9 10.9 ± 7.6
Yes (24) Yes 96.5 ± 0.4 2.9 ± 0.2 0.7 ± 0.2 0 5.3 ± 3.9 10.9 ± 5.9
Yes (36) Yes 93.1 ± 1.6 5.9 ± 1.1 1.0 ± 0.6 0 6.5 ± 3.3 9.7 ± 4.6
2† No (0) No 99.0 0.5 0.5 0 2.0 2.1
No (0) Yes 99.0 0.5 0.5 0 1.3 3.2
Yes (12) Yes 98.2 1.6 0.3 0 4.8 6.0
Yes (24) Yes 96.4 3.1 0.5 0 3.0 9.5
Yes (36) Yes 94.2 5.0 0.9 0 2.8 9.2
3† No (0) No 97.4 2.3 0.4 0 0.6 0.5
No (0) Yes 97.4 2.3 0.4 0 0.6 0.7
Yes (12) Yes 95.3 3.0 1.7 0 0.6 1.8
Yes (24)    Yes 95.7 3.0 1.3 0 1.8 4.0
Yes (36) Yes 92.7 5.8 1.5 0 1.4 3.9
*: mean value of three experiments ± s.d.
†: value of a single experiment
Due to a large biological variation observed between the individual experiments,
significant differences were not found between the absolute mean percentages of EHV-1
antigen-positive cells in the 0, 12, 24 or 36 hours-prestimulated samples and the non-
stimulated control at 12 h pi. However, when relative values were calculated based on the
data of the individual experiments and with the non-stimulated control as a reference
value of 1, a significant difference was observed between the 36 hours-prestimulated
PBMC and the control (relative values were 0.9 ± 0.2, 1.9 ± 1.0, 2.3 ± 0.7 and 3.1 ± 2.3
for the 0, 12, 24 and 36 hours-prestimulated samples, respectively). At 24 h pi, a
significant difference was observed between the absolute percentages of viral antigen-
positive cells in the 12, 24 and 36 hours-prestimulated samples and the non-stimulated
control. For the relative values, a significant difference was found between the 24 and 36
hours-prestimulated samples on the one hand and the non-stimulated control on the other
hand (relative values were 1.6 ± 0.5, 5.7 ± 2.9, 9.1 ± 5.3 and 9.7 ± 7.8 for the 0, 12, 24
and 36 hours-prestimulated samples, respectively). Statistical analysis was based on the
least significant difference (LSD, rejection level 0.050).
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A correlation coefficient r (Pearson’s correlation) between the increase in the
percentage of cells in the S- or G2/M-phase at the moment of inoculation with EHV-1
and the increase in the percentage of EHV-1 antigen-positive cells was calculated for 0,
12, 24 and 36 hours-prestimulated PBMC. The relative values were used for both the
percentage of viral antigen-positive cells and the percentage of cells in the S- and G2/M-
phase. The highest correlation was observed between the relative value of cells in the S-
phase at the moment of inoculation and the relative value of EHV-1 antigen-positive cells
at 12 h pi (r = 0.974). A lower correlation was found between the relative value of cells in
the G2/M-phase and the EHV-1 antigen-positive cells at 12 h pi (r = 0.927), between the
relative value of cells in the S-phase and the EHV-1 antigen-positive cells at 24 h pi (r =
0.909) and, finally, between the relative value of cells in the G2/M-phase and the EHV-1
antigen-positive cells at 24 h pi (r = 0.865). However, all calculated correlations were
significant (t-test, rejection level 0.050).
Formation of clusters of PBMC by stimulation with IONO/PDB
When PBMC were stimulated with IONO/PDB, intercellular contacts were initiated
which resulted in the formation of aggregates or clusters of PBMC, consisting of at least
2 to more than 50 cells (Figure 3.2.1a, page 110). Clusters became manifest between 12
and 24 hours after addition of IONO/PDB and remained clearly visible till at least 60
hours after IONO/PDB addition (end of the experiment).
EHV-1 replication in clusters of IONO/PDB-stimulated PBMC
PBMC were stimulated during 24 hours and infected afterwards. At 8, 17 and 24 h
pi, a double immunofluorescence staining was carried out. The results are shown in Table
3. At 8 h pi, most of the infected clusters contained 1 viral antigen-positive cell (Table 3;
Figure 3.2.1b, page 110). Between 8 and 17 h pi, a 2.2-fold increase in the percentage of
clusters with infected cells was seen and the number of adjacent infected cells per cluster
increased from a maximum of 2 to a maximum of 4 (Table 3; Figure 3.2.1c and d, page
110). The percentages obtained at 24 h pi were similar to those obtained at 17 h pi.
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Table 3.  EHV-1 replication within clusters of IONO/PDB-stimulated PBMC*
Percentage of clusters of PBMC with … adjacent infected cells
Hours post
inoculation
0 1 2 3 4
8 83.3 ± 2.7 15.1 ± 3.5 1.6 ± 1.1 0 0
17 62.6 ± 9.5 24.1 ± 4.5 7.9 ± 1.8 3.0 ± 2.7 2.5 ± 1.3
24 60.6 ± 5.2 25.3 ± 4.3 9.9 ± 1.9 3.6 ± 0.6 0.6 ± 0.9
*: PBMC were stimulated during 24 hours prior to EHV-1 inoculation
All data are expressed as the mean value of 5 experiments ± s.d.
By using confocal laser scanning microscopy, the presence of close intercellular
contacts between adjacent infected cells was visualized in more detail, as shown in Figure
3.2.2a and b (page 110).
Between 8 and 17 h pi, an increase was seen in the percentage of clusters containing
1 infected cell (Table 3). Identification with DH59B, an equine monocyte marker,
revealed that this increase was caused by an increase in the percentage of clusters
containing 1 infected cell, not belonging to the monocytes (from 10.5 ± 4.1 % at 8 h pi to
19.3 ± 4.0 % at 17 h pi).  The percentage of clusters containing 1 infected monocyte, on
the other hand, remained at a constant level (4.6 ± 1.3 % at 8 h pi and 4.9 ± 1.0 % at 17 h
pi). The percentages obtained at 24 h pi were similar to those obtained at 17 h pi.
A similar pattern was seen in the population of cells that remained individually in the
recipient without any visual contact to other cells. In the population of cells, not
belonging to the monocytes, an increase was seen in the percentage of viral antigen-
positive cells between 8 (2.2 ± 1.1 %) and 24 h pi (6.9 ± 6.0 %), whereas a constant
number of monocytes was infected during the entire course of the EHV-1 infection (10.0
± 4.0, 11.0 ± 2.1 and 11.1 ± 3.4 % at 8, 17 and 24 h pi, respectively).
In clusters with 2 or more infected cells in contact, the infected cell groups consisted
of either monocytes and non-monocytes or non-monocytes only (maximum 6.8 ± 4.0 and
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7.6 ± 3.6 % of all the clusters, respectively). Clusters consisting of 2 or more infected
monocytes formed 1.3 ± 1.0 % of all the clusters.
3.2.5 Discussion
The present study shows that stimulation of equine PBMC with IONO/PDB affects
an EHV-1 infection in 2 ways. First, stimulation initiates proliferation events in
lymphocytes, which enable EHV-1 to replicate in a limited number of cells. Second,
stimulation induces the formation of aggregates or clusters of PBMC. The close
interactions between the PBMC within these clusters facilitate the transmission of EHV-1
from an infected cell to an uninfected adjacent cell.
EHV-1 infection was studied in a population of PBMC stimulated with IONO/PDB
during different time periods prior to virus inoculation. PBMC were isolated from
infection-immune, seropositive horses which may be assumed to be latently infected. It
has been described that latent EHV-1 can be reactivated in vitro from leukocytes by the
mitogens phytohaemagglutinin and pokeweed mitogen, as detected by co-cultivation and
immunofluorescence (Smith et al., 1998). Since IONO/PDB also acts as a mitogen, it is
reasonable to suggest, that these products induce reactivation of EHV-1 in the leukocytes
of the three infection-immune horses, thereby confounding the results of the present
study. However, to exclude an influence of reactivation of latenly infected leukocytes on
the percentage of viral antigen-positive cells, we always determined the percentage of
EHV-1 antigen-positive cells in uninoculated PBMC after 0, 12, 24 and 36 of stimulation
(0 h pi). No viral antigen-positive cells were detected (Table 2). Therefore, we may
conclude that stimulation with IONO/PDB did not cause a reactivation of EHV-1 and did
not affect the percentage of EHV-1 antigen-positive cells.
Based on the relative values of viral antigen-positive cells at 12 h pi, a significant
difference was observed between the 36 hours-prestimulated PBMC and the non-
stimulated control. This suggests that stimulation with IONO/PDB induces one or more
specific events that enable EHV-1 to replicate in a limited number of cells. Viral
transmission from cell-to-cell, as will be discussed later on, cannot account for the
increase, since groups consisting of 2 or more adjacent viral antigen-positive cells
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occurred mainly from 14 h pi onwards (data not shown). Moreover, when EHV-1
replication was studied at 8 and 17 h pi in prestimulated PBMC, a 2-fold increase in the
percentage of clusters containing 1 infected lymphocyte (from 10.5 % at 8 h pi to 19.3 %
at 17 h pi) as well as in the percentage of individually located, infected lymphocytes
(from 2.2 % at 8 h pi to 4.4 % at 17 h pi) was observed. Since there is no direct
interaction with other infected cells, these observations support the idea that the increase
in the percentage of infected cells is not caused by cell-to-cell transmission of the virus,
but by another effect induced by the mitogens, for example one or more cell cycle-
dependent events.
To determine whether the effect, induced by IONO/PDB, was related to the S-phase
or the G2/M-phase of the cell cycle, the correlation coefficient (r) was calculated between
the relative value of cells in the S- or G2/M-phase of the cell cycle at the moment of
inoculation and the relative value of EHV-1 antigen-positive cells. A very high
correlation (r = 0.974) was observed between the relative value of cells in the S-phase
and the relative value of EHV-1 antigen-positive cells at 12 h pi. This means that an
increase in the percentage of cells in the S-phase after a certain time interval of
prestimulation is accompanied by a similar increase in the percentage of EHV-1 antigen-
positive cells at 12 h pi. Therefore, we assume that viral replication is facilitated during a
specific stage of the S-phase of the cell cycle. This is consistent with a previous report by
Lawrence (1971), who found evidence for a relationship between EHV DNA-synthesis
and the S-phase of the cell cycle in KB cells, a human carcinoma cell line. Since most
cells entering the S-phase will continue into the G2/M-phase, a significant, but lower,
correlation was found between the relative value of cells in the G2/M-phase and the
relative value of EHV-1 antigen-positive cells at 12 h pi. At 24 h pi, there was still a
significant correlation between the different phases of the cell cycle and the relative
percentage of EHV-1 antigen-positive cells. However, the correlation coefficients were
clearly lower than at 12 h pi, suggesting that also other effects are involved at this time
point after inoculation.
We hypothesized that the close intercellular interactions formed within the clusters
of IONO/PDB-stimulated equine PBMC favoured the transmission of EHV-1 from an
infected to an uninfected adjacent cell. Our results show that EHV-1 was indeed
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transferred from infected cells to adjacent cells.  At 8 h pi, only 1.6 % of the clusters
contained a group of adjacent infected cells, whereas this percentage significantly
increased to 13.4 % at 17 h pi. Moreover, the number of adjacent infected cells per cluster
increased from a maximum of 2 at 8 h pi to a maximum of 4 at 17 and 24 h pi. With
confocal laser scanning microscopy the existence of close intercellular contacts between
adjacent infected cells was confirmed. The exact mechanism by which EHV-1 is
transmitted from one cell to another within the clusters of PBMC remains to be
determined. Since addition of virus-neutralizing antibodies in the medium during
infection did not alter the percentage of infected clusters or the number of adjacent
infected cells per cluster (data not shown), we suggest that a direct cell-associated spread
of the virus is involved. Since cluster formation seems to be required for transmission and
since cluster formation depends on discrete interactions between cell adhesion molecules
(reviewed by Hogg and Landis), it seems likely that EHV-1 transmission relies on the
close contacts initiated by cell adhesion molecules, as described for human
immunodeficiency virus (Fais et al., 1995; Tsunetsugu-Yokota et al., 1997).
The results of the present study concerning the subfractions of lymphocytes that
were scored as infected differed from those obtained by Scott et al. (1983). However, it is
important to mention that the study of Scott et al. was performed in vivo. They
experimentally infected ponies to detect and quantitate the in vivo presence of the virus in
leukocytes. Cultivation and identification were performed on cells obtained from the
infected ponies. In the present study, the interaction between leukocytes and EHV-1 was
studied in vitro. Leukocytes were isolated from healthy horses and, afterwards, stimulated
and infected in vitro. Furthermore, Scott et al. used infectious centre assays and plaque
assays to detect the infected cells and, therefore, their results represent the “productively
infected” leukocytes. In our experiments, an immunofluorescence staining was used and,
therefore, the results represent the “viral antigen-positive” leukocytes. In our previous
report, we demonstrated that only 13.7 % of the viral antigen-positive monocytes and 5.3
% of the viral antigen-positive lymphocytes were productively infected. This means that
the number of viral antigen-positive cells will be quite different from the number of
productively infected cells. The above-mentioned differences may be the cause of the
disparity between the study of Scott et al. and the present study.
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Remarkably, one-third of the PBMC could not be identified by the markers used in
our experiments. This finding cannot be due to an effect of infection, since the same
observation was made in non-infected cells (30.1 ± 5.7 % unidentified). Modulation of
the expression of cell surface molecules in response to phorbol esters has been described
in horses by Zhang et al. (1994). Since they found that phorbol-12-myristate-13-acetate
(PMA)-mediated down-regulation of CD4 expression was reversible and the percentage
of CD4+ molecules was returned to control levels after 48 hours (Zhang et al., 1994), it
seems unlikely that the PMA stimulation is responsible for the loss of expression of
leukocyte markers on PBMC in this study. Whether a synergistic effect of PDB and
IONO, as described in mice by Anderson and Coleclough (1993), causes a more
extensive and long-lasting down-regulation of surface molecules in equine T-
lymphocytes than PDB alone has not been determined as it remained outside the scope of
this study.
We can conclude from this study that mitogen stimulation positively influences an
EHV-1 infection in 2 ways: (i) by initiating specific cell cycle events and (ii) by inducing
the formation of clusters of PBMC, thereby facilitating transmission of EHV-1 from cell
to cell.
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4.1.1 Summary
Equine herpesvirus 1 (EHV-1) may cause abortion in vaccination- and infection-
immune horses. EHV-1-infected peripheral blood mononuclear cells (PBMC) play an
important role in the escape of the virus from immunity. We examined how infected
PBMC can avoid destruction by EHV-1-specific antibody and equine complement. The
majority of EHV-1-infected PBMC (68.6 %) lacked surface expression of viral antigens
and these cells were not susceptible to complement-mediated lysis. In infected PBMC
with surface expression of viral antigens, 63 % showed focal and 37 % showed general
surface expression. General surface expression rendered infected PBMC susceptible to
lysis by antibody and complement (from 5.4 to 31.2 % lysed cells depending on antibody
and complement concentration). Infected PBMC with focal surface expression showed
significant lysis only in the presence of high antibody and complement concentrations.
Thus, absence of surface expression protects infected PBMC against complement-
mediated lysis.
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4.1.2 Introduction
Equine herpesvirus 1 (EHV-1), an Alphaherpesvirus, is an important pathogen of
horses. After exposure, EHV-1 replicates in the respiratory tract. Replication is followed
by a leukocyte-associated viremia, enabling EHV-1 to reach internal organs where its
replication can result in abortion, neonatal death or nervous system disorders (Allen and
Bryans, 1986). Viremia may occur in the presence of virus-neutralizing antibodies in
infection-immune (Doll and Bryans, 1963; Gleeson and Coggins, 1980; Mumford et al.,
1987) and vaccination-immune horses (Bürki et al., 1990; Heldens et al., 2001).
Apparently, recognition of circulating EHV-1-infected peripheral blood mononuclear
cells (PBMC) by the antibody-mediated immune system is inefficient.
Following infection of cells with enveloped viruses, viral glycoproteins are
incorporated in cellular membranes. Binding of virus-specific antibodies to glycoproteins
present in the plasma membrane makes infected cells recognizable for the classical
complement pathway, phagocytes and natural killer (NK) cells, leading to lysis of the cell
(Harper, 1994). Several herpesviruses have developed strategies to avoid antibody-
dependent cell lysis. For suid herpesvirus 1 (SuHV-1)-infected monocytes, addition of
SuHV-1-specific antibodies results in clearance of viral glycoproteins from the plasma
membrane by antibody-induced internalization (Favoreel et al., 1999). Clearance of the
plasma membrane renders infected monocytes significantly less susceptible towards
antibody-dependent, complement-mediated lysis (Van de Walle et al., in press). In human
cytomegalovirus (HCMV)-infected monocyte-derived macrophages, transport of viral
glycoproteins to the plasma membrane is prevented, due to destruction of the microtubule
network (Fish et al., 1996). Absence of HCMV glycoproteins on the cell surface may be
another strategy to avoid recognition by the antibody-dependent immune responses.
Finally, several herpesviruses are known to encode proteins that interfere with activation
of the complement cascade (reviewed by Favoreel et al., 2000).
The main purpose of the present study was to investigate how EHV-1-infected
PBMC are able to avoid recognition and destruction by the antibody-dependent immune
responses.
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4.1.3 Materials and methods
Cells
PBMC were isolated from adult, infection-immune horses by density centrifugation
on Ficoll-Paque (Pharmacia Biotech AB, Uppsala, Sweden). After isolation, PBMC were
incubated during 24 hours in medium, supplemented with ionomycin (IONO) (0.5 mM)
and phorbol dibutyrate (PDB) (10 nM) (Sigma, Bornem, Belgium) to favour EHV-1
replication (van der Meulen et al., 2001). Rabbit kidney (RK13) and equine embryonic
lung (EEL) cells were maintained in MEM with 5 % fetal bovine serum, 100 U/ml
penicillin, 0.1 mg/ml streptomycin, 0.1 mg/ml kanamycin and 0.3 mg/ml glutamin, until
trypsinisation and inoculation.
Virus and in vitro infection
All cells were inoculated with the Belgian EHV-1 strain 97P70 at a multiplicity of
infection of 10 (van der Meulen et al., 2000). After 1 hour incubation, cells were washed
and cultured at 37 °C. To ensure that the percentages of infected PBMC obtained in the
present study, were not confounded by a possible reactivation in or re-infection of the
horses during the sampling period, we always included stimulated but non-inoculated
PBMC. Viral antigen expression was never detected in these control samples.
Immunofluorescence stainings
Cell surface and intracellular expression of EHV-1 antigens in PBMC were
examined by means of a double immunofluorescence staining at 0, 6, 9, 12 and 24 hours
post inoculation (h pi). PBMC were fixed with paraformaldehyde (3 %) and viral proteins
on the surface were stained with polyclonal, fluoresceine isothyocyanate (FITC)-labeled
horse anti-EHV-1 immunoglobulin (Ig) G. Intracellular viral proteins were stained upon
permeabilisation with saponin (0.1 %) using polyclonal, biotinylated anti-EHV-1 IgG and
streptavidin-Alexa Fluor® 350 (Molecular Probes, Eugene, OR, USA). Anti-EHV-1 IgG
was raised by hyperimmunization of a horse. An infection-immune horse was inoculated
intranasally with EHV-1 strain 97P70. After 2 weeks, a second immunization was
performed intramuscularly using the same virus strain mixed with adjuvans (Suvaxyn“
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Aujeszky im o/w, Fort Dodge Animal Health, Benelux). Two weeks later, serum was
collected. IgG was purified on a protein G column and labeled with FITC (Becton
Dickinson, San Jose, CA, USA) or biotinylated (Amersham International,
Buckinghamshire, UK) following the manufacturer’s instructions.
To determine if expression of viral antigens on the surface relied on the cell type,
EEL and RK13 cells were examined at 12 h pi using the immunofluorescence staining as
described before. For PBMC, an additional step was included prior to permeabilisation,
using monoclonal antibodies HT23A (anti-equine CD5), 1.9/3.2 (anti-equine B-
lymphocytes) or DH59B (equine monocyte marker) (VMRD, Pullman, WA, USA)
followed by goat anti-mouse-Texas Red® (Molecular Probes, Eugene, OR, USA),
allowing identification of different PBMC subpopulations.
Antibody-dependent, complement-mediated cell lysis (ADCML) assay
To examine the effect of antibody and complement on the viability of EHV-1-
infected PBMC with and without surface expression, PBMC were infected for 24 hours
and, subsequently, incubated for 1 hour at 37 °C with the previously described FITC-
labeled anti-EHV-1 antibodies. IgG concentrations ranged from 0 to 1.6 mg IgG per ml.
Afterwards, different concentrations of unheated EHV-1-negative horse serum were
added during 1 h at 37 °C as a source of complement. The maximum concentration of
serum was 20 %, since higher concentrations were cytotoxic. Ethidium monoazide
bromide (EMA) (Molecular Probes, Eugene, OR, USA) was then added during 30 min at
4 °C to stain the nucleus of lysed cells. No photocrosslinking of EMA was performed,
since it reduced the fluorescence intensity of the FITC-labeled antibodies and did not
affect the observed percentages of lysed cells when compared to non-photocrosslinked
samples (data not shown). Finally, intracellular viral proteins were stained upon fixation
and permeabilisation as described earlier. In order to visualize surface expression in
PBMC incubated in the absence of FITC-labeled antibodies during the first step of the
assay, an additional labeling step was included in between fixation and permeabilisation.
For that, the polyclonal, FITC-labeled anti-EHV-1 IgG was used.
To determine whether lysis was complement-mediated, the assay was repeated in the
presence of ethylenediamine tetra-acetic acid (EDTA). EDTA is a Ca2+- and Mg2+-
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chelator that blocks activation of the complement system in different species, including
the horse (Joseph et al., 1975; Leid et al., 1985; Friedman et al., 2000). EDTA (10 mM)
was added 30 minutes before and during complement incubation. Antibody and serum
concentration used were 0.8 mg/ml and 20 %, respectively.
Fluorescence and confocal laser scanning microscopy
Cells were analyzed using an inverted fluorescence microscope (Leica DM IRBE,
Leica Microsystems Holdings GmbH, Wetzlar, Germany). Confocal images were
obtained using a Bio-rad Radiance 2000 MP confocal laser scanning system attached to
an inverted microscope (Nikon, Eclipse TE300, Japan).
Statistics
Mean values were obtained from the data of at least three independent experiments.
Statistical analysis was based on analysis of variance (ANOVA) with a rejection level of
0.050 using SPSS (SPSS Inc., Chicago, Illinois, USA)
4.1.4 Results
Cell surface expression of viral antigens in EHV-1-infected PBMC
Only if intracellular expression of viral antigens was present, cells were considered
for further examination on a possible surface expression. Total percentages of infected
cells were 2.0 ± 1.3 % at 6 h pi, 4.3 ± 1.9 % at 9 h pi, 6.6 ± 1.2 % at 12 h pi and 14.2 ±
4.3 % at 24 h pi. Of these infected PBMC, 4.0 ± 0.8 % showed cell surface expression at
6 h pi, 14.4 ± 3.7 % at 9 h pi, 26.8 ± 6.9 % at 12 h pi and 31.4 ± 4.5 % at 24 h pi. Thus,
only a minority of EHV-1-infected PBMC showed expression of viral antigens on their
surface. Among these, two-thirds expressed antigens on part of the cell surface only, a
status further designated as ‘focal expression’, whereas the remaining expressed EHV-1
antigens on the entire surface, a status further designated as ‘general expression’. No
differences were observed in the ratio of these expression patterns between the various
time points post inoculation. Figure 4.1.1 (see page 111) represents confocal images of an
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EHV-1-infected PBMC without surface expression (a), with focal expression (b), and
with general expression (c).
Cell surface expression of viral antigens in different cell types upon EHV-1 infection
EHV-1 antigens were present on the surface of 12.6 ± 3.0 % of infected T-
lymphocytes, 12.2 ± 1.8 % of infected B-lymphocytes, 25.7 ± 8.7 % of infected
monocytes, 11.0 ± 5.6 % of infected EEL cells and 13.0 ± 1.0 % of infected RK13 cells.
Thus, cell surface expression was absent on the majority of infected cells independently
of the cell type.
ADCML of EHV-1-infected PBMC with and without cell surface expression
Table 1 presents the percentages of lysed PBMC when using varying antibody (a)
and complement (b) concentrations in the ADCML assay. A minimal number of 100 cells
were scored per data point.
In non-infected PBMC, between 1.2 and 2.2 % of the cells were lysed and addition
of antibodies and complement had no effect on viability. For infected PBMC without cell
surface expression, percentages of lysed cells were similar to that in non-infected PBMC.
For infected PBMC showing focal surface expression, the percentage of lysed cells was
only significantly higher compared to non-infected PBMC when an antibody
concentration of 1.6 mg/ml and a serum concentration of 20 % were used (8.3 %). For
infected PBMC showing general surface expression, between 19.4 and 31.2 % of the cells
were lysed in the presence of antibodies and complement, which was significantly higher
compared to non-infected cells. When complement was added in the absence of
antibodies, 10.5 % of PBMC showing general surface expression were lysed, whereas
addition of antibodies in the absence of complement resulted in 5.4 % lysed cells.
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Table 1.  Complement-mediated cell lysis in EHV-1-inoculated PBMC
a.  The effect of antibodies
Percentage of lysed cells in …
Non-infected PBMC Infected PBMC
Antibody
(mg/ml)
Complement
(% horse serum)
without
surface
expression
with focal
surface
expression
with general
surface
expression
0 0 1.2 ± 0.4 1.2 ± 0.5 2.0 ± 0.9 2.2 ± 1.2
0 20 2.2 ± 0.8 1.5 ± 0.8 2.2 ± 0.8 10.5 ± 1.6
0.4 20 1.7 ± 0.8 3.6 ± 0.7 4.3 ± 0.9 28.3 ± 3.3
0.8 20 2.0 ± 0.4 2.5 ± 0.4 3.8 ± 1.5 27.6 ± 3.6
1.6 20 1.9 ± 0.4 2.6 ± 0.3 8.3 ± 1.4 31.2 ± 5.0
b.  The effect of complement
Percentage of lysed cells in …
Non-infected PBMC Infected PBMC
Antibody
(mg/ml)
Complement
(% horse serum)
without
surface
expression
with focal
surface
expression
with general
surface
expression
0 0 1.2 ± 0.4 1.2 ± 0.5 2.0 ± 0.9 2.2 ± 1.2
0.8 0 1.3 ± 0.8 0.8 ± 0.1 2.0 ± 0.4 5.4 ± 1.7
0.8 5 1.2 ± 0.6 1.8 ± 1.1 5.1 ± 0.8 19.4 ± 2.5
0.8 10 1.7 ± 0.3 1.2 ± 0.6 3.7 ± 0.9 20.0 ± 1.6
0.8 20 2.0 ± 0.4 2.5 ± 0.4 3.8 ± 1.5 27.6 ± 3.6
All data are expressed as the mean value of at least three experiments ± SD.
In contrast to infected PBMC without and with focal surface expression, PBMC
showing general surface expression are apparently destroyed by three different immune
mechanisms. Binding of antibodies to the surface of these infected PBMC in the absence
of complement triggered destruction most likely via antibody-dependent, cell-mediated
cytotoxicity. Lysis by complement in the absence of antibodies most likely occurred via
the antibody-independent, complement-mediated pathway, whereas addition of antibodies
increased the percentage of lysed cells by activation of the antibody-dependent,
complement-mediated pathway. Figure 4.1.2 (see page 111) shows confocal images of a
lysed, infected PBMC expressing viral antigens on the entire cell surface (a) and a viable,
infected PBMC without cell surface expression (b), respectively.
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Addition of EDTA significantly reduced the percentage of lysed PBMC showing
general surface expression from 27.6 ±  3.6 to 8.8 ±  2.8 %, thereby demonstrating
involvement of complement in the process of lysis. The percentages of lysed cells in
infected PBMC without and with focal surface expression showed a slight increase to 3.9
± 1.3 and 5.6 ± 2.3 %, respectively. The increase was due to cytotoxic effects of EDTA,
since it was also observed when EDTA was used alone, in the absence of antibodies and
complement.
4.1.5 Discussion
The present study describes a potential strategy of immune evasion for EHV-1-
infected PBMC. We demonstrate that the majority of EHV-1-infected PBMC lacks cell
surface expression of viral antigens. Absence of surface expression protects infected
PBMC from lysis by equine complement.
Infected PBMC showing focal cell surface expression could escape from
complement-mediated lysis as well. Circumvention of antibody-dependent, complement-
mediated lysis may be explained by the fact that efficiency of lysis depends on the
amount of antibody bound per infected cell (Joseph et al., 1975; Perrin et al., 1976;
Sissons et al., 1979). In our study, the extent of antigen expression on the surface of
infected PBMC showing focal expression varied from only a small area of expression to
an almost complete surface expression. It is very well possible that only cells with more
extensive antigen expression may bind enough IgG to induce cell lysis. How infected
PBMC without surface expression and with focal surface expression escape from
antibody-independent, complement-mediated lysis seems less obvious. Analogous to the
antibody-dependent pathway, the extent of antigen expression on the surface of infected
cells may be important in turning the scale for either prevention or activation of the
antibody-independent, complement-mediated pathway.
The maximal percentage of lysed PBMC showing general surface expression was
31.2 %. This suggests that the efficiency of equine complement to lyse EHV-1-infected
PBMC is rather low. A low efficiency of equine complement, both of the antibody-
independent and the antibody-dependent pathway, compared to other mammalian species
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has already been described by Ish et al. (1993). Low efficiency of complement in our
study may also result from viral interference with the complement cascade. For herpes
simplex virus (HSV), varicella-zoster virus (VZV) and SuHV-1, it has been demonstrated
that the viral glycoprotein complex gE/gI displays Fc receptor activity, which interferes
with efficient antibody-dependent complement activation (Johnson et al., 1988; Frank
and Friedman, 1989; Litwin et al., 1992; Favoreel et al., 1997; Nagashunmugam et al.,
1998; Van de Walle et al., in press). Homologues of gE and gI are also expressed by
EHV-1 (Audonnet et al., 1990; Elton et al., 1991; Telford et al., 1992), but whether they
exert Fc receptor activity is not yet known. Glycoprotein gC of HSV, VZV, EHV-1 and
4, SuHV-1 and bovine herpesvirus 1 (BoHV-1) is capable of binding with complement
factor C3, a pivotal component of complement activation, which may result in inhibition
of the antibody-independent pathway (Friedman et al., 1984; Harris et al., 1990; Huemer
et al., 1992, 1993, 1995).
In conclusion, at least two-thirds of EHV-1-infected PBMC lack cell surface
expression of viral antigens. Absence of surface expression was observed independently
of the subtype of PBMC and protects infected cells from antibody-dependent and
antibody-independent lysis by equine complement.
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4.2 EXPRESSION OF VIRAL ANTIGENS AND MHC CLASS I O N
THE SURFACE OF EQUINE HERPESVIRUS 1-INFECTED
BLOOD MONONUCLEAR CELLS DURING VIREMIA IN
IMMUNE PONIES
___________________________________________Veterinary Microbiology, submitted
van der Meulen, K., Nauwynck, H. and Pensaert, M.
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4.2.1 Summary
Previous in vitro studies demonstrated that the majority of equine herpesvirus 1
(EHV-1)-infected peripheral blood mononuclear cells (PBMC) lack viral antigen
expression on their cell surface. Absence of cell surface expression protects infected
PBMC from complement-mediated lysis in vitro and represents a potential strategy of
immune evasion. The purpose of the present study was to examine if infected PBMC lack
surface expression of viral antigens during viremia upon experimental inoculation of
immune ponies. Moreover, surface expression of major histocompatibility complex
(MHC) class I molecules was examined in infected cells, since MHC class I molecules
present viral peptides to cytotoxic T-lymphocytes (CTL) and thus also play a role in
making infected cells recognizable for the immune system. Four infection-immune ponies
and 1 EHV-1-negative control pony were inoculated with the Belgian EHV-1 strain
97P70. PBMC were collected at various time points between 0 and 28 days post
inoculation (d pi). Surface expression of viral antigens and MHC class I molecules on
EHV-1-infected PBMC was determined by immunofluorescence labeling. Cell surface
expression of viral antigens was present in only 1 EHV-1-infected PBMC in the immune
ponies (1/31) and in none of the EHV-1-infected PBMC in the non-immune pony (0/18).
MHC class I expression was found on 80 to 100 % of EHV-1-infected PBMC in both the
immune ponies and the non-immune pony, which was similar as observed in non-infected
PBMC (83 - 100 %). In conclusion, lack of surface expression of viral antigens, but not
of MHC class I molecules, may allow EHV-1-infected PBMC to avoid recognition by the
immune system.
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4.2.2 Introduction
Equine herpesvirus 1 (EHV-1), an Alphaherpesvirus, is an important pathogen of
horses worldwide. After infection, EHV-1 replicates in epithelia of the respiratory tract
and, subsequently, spreads to regional lymph nodes (Patel et al., 1982; Kydd et al.,
1994a, 1994b). In young horses, virus replication in the respiratory tract may result in
acute respiratory disease (Allen and Bryans, 1986). Primary replication is followed by an
extensive cell-associated viremia which lasts until 9 to 27 days after infection (Thein and
Brown, 1988; Gibson et al., 1992; McCartan et al., 1995). Carried by infected peripheral
blood mononuclear cells (PBMC), mainly T-lymphocytes, EHV-1 spreads to internal
organs, where its replication within endothelium of the vasculature may cause late term
abortion or myeloencephalopathy (Scott et al., 1983; Allen and Bryans, 1986).
Protective immunity resulting from EHV-1 infection is of short duration. Despite
persistence of virus-neutralizing antibodies, the respiratory mucosa may be
asymptomatically re-infected within 2 to 4 months (Doll, 1961; Gibson et al., 1992).
Notwithstanding the presence of high levels of systemic antibodies (Doll and Bryans,
1963; Gleeson and Coggins, 1980; Bryans and Allen, 1982; Burrows et al., 1984; Frymus
et al., 1986; Mumford et al., 1987; Bürki et al., 1990; van der Meulen et al., 2000a;
Heldens et al., 2001) and EHV-1-specific cytotoxic T-lymphocyte (CTL) precursors
(O’Neill et al., 1999), EHV-1-infected PBMC can be detected in the blood circulation
upon challenge of both infection-immune and vaccination-immune horses. This means
that infectious virus can still be delivered to permissive endothelial cells and,
consequently, cause abortion or nervous system disorders even though horses possess an
active immunity.
Following infection with enveloped viruses, viral glycoproteins are incorporated in
the plasma membrane of infected cells. Subsequent binding of virus-specific antibodies to
these glycoproteins leads to recognition and destruction of infected cells via the classical
complement pathway, phagocytes and natural killer (NK) cells (Harper, 1994). Recent in
vitro studies on EHV-1-infected PBMC demonstrated that 70 % of the infected cells lack
visually detectable levels of viral glycoproteins on their surface and that this protects the
infected cells from lysis by equine complement (van der Meulen et al., 2003). The
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hypothesis is put forward that absence of viral antigens on the surface of EHV-1-infected
PBMC also occurs in vivo, thereby providing a potential strategy for infected PBMC to
escape from antibody-mediated immune responses in the horse.
Major histocompatibility complex (MHC) class I molecules play an important role in
the destruction of virus-infected cells in a cell-mediated fashion. Once a cell is infected,
newly produced viral proteins become degraded into peptides. These peptides are then
loaded onto MHC class I molecules and transported to the cell surface, where their
presentation results in recognition and lysis of infected cells by CTL (Harper, 1994). In
vitro, several herpesviruses are known to affect MHC class I processing and loading,
leading to retention or untimely degradation of these molecules in the cell. Furthermore,
some herpesviruses are known to directly inhibit MHC class I - viral peptide trafficking
to the surface of infected cells (reviewed by Favoreel et al., 2000). In vivo, such
phenomenon may result in inefficient recognition of virus-infected cells by CTL, thereby
enabling them to circumvent destruction by the cell-mediated immunity.
The main purpose of the present study was to examine whether infected PBMC,
present in the circulation of immune horses upon EHV-1 exposure, lack expression of
viral antigens and/or MHC class I molecules on their cell surface.
4.2.3 Materials and methods
Virus
A 5th passage of EHV-1 strain 97P70 was used for experimental inoculation (van der
Meulen et al., 2000b). Virus was propagated on equine embryonic lung cells.
Animals
Four adult ponies and 1 pony foal were used in the present study. The adult ponies
(A-D) were aged between 5 and 15 years and had been previously infected with EHV-1,
as evidenced by the presence of antibodies at the start of the experiment using a
complement-dependent seroneutralization (SN)-test or the more sensitive
immunoperoxidase monolayer assay (IPMA), as described later. Pony E, a 9-month old
foal, had no detectable EHV-1-specific antibody titres in either the SN-test or the IPMA
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and was included as a control. To ensure that the foal was not latently infected, an
attempt was made to reactivate virus using dexamethasone treatment. Dexamethasone
natriumphosphate (Certa International, Braine-l’Alleud, Belgium) was administered 1
month prior to EHV-1 inoculation by intravenous injection at a dose of 2 mg/kg daily for
three consecutive days (Gibson et al., 1992; Slater et al., 1994). Three weeks after
dexamethasone administration, a complement-dependent SN-test and an IPMA were
performed. Absence of detectable antibody titres ruled out a possible reactivation, thereby
confirming the EHV-1-negative status of pony E.
All ponies were housed inside isolated stables. They were fed daily with a
commercial, complete feed. Drinking water and hay were supplied ad libitum.
Experimental inoculation
Each pony was inoculated oronasally with 20 ml of a virus suspension containing
106.8 tissue culture infectious dose 50 (TCID50). Ten ml were administrated intranasally (5
ml per nostril) and 10 ml were inoculated orally. The virus titre was confirmed by
titration of the inoculum.
Clinical observation
Following virus inoculation, the ponies were monitored daily for clinical signs via
physical examination and measurement of rectal temperatures. Rectal temperatures ≥
38.5 °C were regarded as fever.
Sampling procedure
A nasopharyngeal mucus sample and 100 ml of heparinized blood were taken at 0, 1,
3, 5, 7, 9,14, 21 and 28 days post inoculation (d pi).
Nasopharyngeal samples were collected using a swab with a length of 40 cm that
was inserted through the nostrils up to the nasopharynx. Immediately after collection,
swabs were immersed in transport medium containing phosphate-buffered saline
supplemented with 10 % fetal bovine serum, 1000 U/ml penicillin, 1 mg/ml streptomycin,
0.5 mg/ml kanamycin and 0.1 mg/ml gentamycin.
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Heparinized blood was separated in PBMC and plasma immediately after collection
by means of density gradient centrifugation on Ficoll Paque (Amersham Pharmacia
Biotech AB, Uppsala, Sweden).
Virological examination
EHV-1 was titrated in the nasopharyngeal secretions. Therefore, nasopharyngeal
swabs were vortexed in the transport medium, the medium was then centrifuged and the
supernatant was titrated on monolayers of rabbit kidney (RK13) cells.
Immediately after separation from whole blood, PBMC were co-cultivated to
determine the number of infected cells. Briefly, 1 x 107 PBMC were placed on a
monolayer of RK13 cells. The monolayers were overlayed with carboxymethylcellulose
(0.94 %), centrifuged for 30 min at 750 x g and incubated at 37 °C and 5 % CO2.
Monolayers were checked daily for plaques.
An additional sample of freshly isolated PBMC was freeze-thawed twice and the cell
lysate was titrated for the presence of intracellular infectious virus.
Plasma samples were examined for the presence of extracellular virus by means of
isolation on RK13 cells.
Immunofluorescence
In order to determine whether viral antigens and/or MHC class I molecules were
expressed on the cell surface of EHV-1-infected PBMC during viremia, a double
immunofluorescence labeling was performed. First, PBMC were fixed with
paraformaldehyde (3 %) immediately after isolation and incubated with either protein G-
purified, fluoresceine isothyocyanate (FITC)-labeled polyclonal horse anti-EHV-1
antibodies (van der Meulen et al., 2003) or with the mouse monoclonal antibody PT85A
directed against equine MHC class I (VMRD, Pullman, WA, USA) followed by goat
anti-mouse FITC. Second, PBMC were permeabilized with saponin (0.1 %) and
incubated with protein G-purified, biotinylated polyclonal horse anti-EHV-1 antibodies,
followed by streptavidin-Texas Red® (Molecular Probes, Eugene, OR, USA). After
staining, cells were placed on cover slips and analyzed using fluorescence (Leica DM
BRE, Leica Microsystems GmbH, Wetzlar, Germany) and confocal laser scanning
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microscopy (Leica TCS SP2 laser scanning spectral confocal system, Leica Microsystems
GmbH, Wetzlar, Germany). For each sample, approximately 0.4 x 107 cells were
analyzed.
Serological examination
The SN titre was determined at 0, 7, 14, 21 and 28 d pi by means of a complement-
dependent SN-test. Two-fold serum dilutions were prepared in duplicate rows of 96-well
microtiter plates using MEM as diluent and mixed with 300 TCID50 of the EHV-1 isolate
97P70. After 23 hours of incubation at 37 °C and 5 % CO2, unheated guinea pig serum
was added to each well as a source of complement. Plates were then incubated for an
additional hour and the content of each well was subsequently transferred to a monolayer
of RK13 cells.  Monolayers were incubated at 37 °C and 5 % CO2 and examined for
cytopathic effect after 5 days. The SN titre was calculated as the reciprocal value of the
serum dilution that neutralized cytopathic effect in 50 % of the wells.
In case no detectable SN titre was observed, serum samples were tested using the
more sensitive IPMA. RK13 cells were seeded in 96-well microtiter plates, grown to
confluency and inoculated with 103 TCID50 per well of the EHV-1 isolate 97P70. After 28
hours, cells were washed, dried at 37 °C for 1 hour and stored at -20 °C until use. Plates
were then thawed and subsequently fixed with 4 % paraformaldehyde and a solution
containing 1 % hydrogen in methanol. Following extensive washing, serial 2-fold
dilutions of the sera were added and cells were incubated for 1 hour at 37 °C. Then, cells
were incubated with peroxidase-labeled goat anti-horse antibodies (Jackson
ImmunoResearch Laboratories Inc., PA, USA). After 1 hour, a substrate solution of 3-
amino-9-ethylcarbazole in 0.05 M acetate buffer with 0.05 % hydrogen was added to
each well. Following 20 minutes of incubation at 37 °C, substrate solution was replaced
with acetate buffer to block the enzymatic staining reaction. The IPMA titre was
calculated as the reciprocal value of the highest serum dilution that induced visual
staining of infected RK13 cells, as determined by light microscopy.
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4.2.4 Results
Clinical observation
The clinical signs as observed in the EHV-1-inoculated ponies are summarized in
Table 1. Clinical signs were mild and very similar in the immune ponies and in the non-
immune pony, except for swelling of the lymph nodes, which was observed only in the
non-immune pony. Additionally, the peak temperature observed in the non-immune pony
(40.2 °C at 1 d pi) was higher than that observed in the infection-immune animals (39.3
°C in pony D at 8 d p.i). In the immune pony B, the observed tachypnee caused severe
discomfort and did not improve during the course of time. Therefore, the animal was
treated with antibiotics (Duplocillin® L.A., Mycofarm Belga, Mechelen, Belgium ) at 16,
18 and 21 d pi, which resulted in a full recovery.
Table 1.  Clinical signs in ponies following experimental inoculation with EHV-1
Pony Duration of clinical signs (from … to … d pi)
pyrexia nasal discharge tachypnee swelling lnn*
Status at
inoculation
SN (IPMA)
titre at
inoculation
serous purulent
A immune 48 - 2 - 9 - - -
B immune 32 6 - 11 2 - 12 - 6 - 17 -
C immune 4 - 2 - 10 - - -
D immune < 2 (10) 7 - 10 2 - 10 7 8 - 9 -
E non-immune < 2 (< 10) 1 - 2 /
   4 - 5
2 - 12 - - 2 – 23
*: submandibular and retropharyngeal lymph nodes
Virus isolation from the upper respiratory tract
The results of virus isolation from the nasopharyngeal swabs are shown in Table 2.
All ponies shed virus on day 1 pi. For the immune ponies, the duration of virus excretion
was 1 day in pony A, 5 days in ponies B and C, and 3 days in pony D. The non-immune
pony E shed virus for 14 days.
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Table 2.  Virus shedding and viremia in ponies following an experimental
inoculation with EHV-1
Pony Status at
inoculation
SN (IPMA)
titre at
inoculation
1 Virus titre (log10 TCID50/gr nasopharyngeal mucus)
2 No. of plaques/107 PBMC (co-cultivation)
3 No. of infected cells/0.8x107 PBMC (IF)
at … d pi
0 1 3 5 7 9 14 21 28
A immune 48 (1) - 4.6 - - - - - - -
(2) 0 0 0 1 5 2 0 0 0
(3) 0 0 0 4 3 4 2 0 0
B immune 32 (1) - 4.3 4.8 4.5 - - - - -
(2) 0 0 0 14 2 0 1 + 0
(3) 0 0 1 2 3 3 1 1 0
C immune 4 (1) - 2.5 3.3 5.3 - - - - -
(2) 0 0 0 8 2 0 0 0 0
(3) 0 1 1 1 4 2 2 1 0
D immune < 2 (10) (1) - 4.5 3.8 - - - - - -
(2) 0 0 0 0 4 1 0 0 0
(3) 0 2 3 2 3 1 2 0 0
E < 2 (< 10) (1) - 5.9 5.0 3.9 3.6 3.6 3.1 - -
(2) 0 0 2 20 18 6 1 0 0
non-
immune
(3) 0 3 7 10 6 3 3 3 0
-: < 0.8 log10 TCID50 per gram nasopharyngeal mucus
IF: immunofluorescence
+: plaques were present, but the number could not be determined
Viremia
The numbers of infected PBMC as determined by co-cultivation and
immunofluorescence labeling are also presented in Table 2. In the immune ponies,
infected PBMC were detected by co-cultivation between 5 and 9 d pi, 5 and 7 d pi and 7
and 9 d pi in pony A, C and D, respectively. For pony B, PBMC were positive at 5 and 7
d pi and at 14 and 21 d pi, but no virus was recovered at 9 d pi. In the non-immune pony
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E, cell-associated viremia was detected between 3 and 14 d pi. In none of the 5 ponies,
virus was recovered from the cell lysate of PBMC or from plasma.
Infected PBMC as determined by immunofluorescence labeling were observed from
5 till 14 d pi, from 3 till 21 d pi, from 1 till 21 d pi and from 1 till 14 d pi in the immune
ponies A, B, C and D, respectively. In the non-immune pony E, infected PBMC were
found from 1 till 21 d pi (Table 2).
For the immune ponies, expression of viral antigens on the surface of EHV-1-
infected PBMC was only observed in pony A in 1 out of 8 examined EHV-1-infected
PBMC (14 d pi). In the immune ponies B, C and D, all examined EHV-1-infected PBMC
lacked visually detectable levels of plasma membrane-anchored viral antigens (0/7, 0/8
and 0/8 infected PBMC, respectively). Also in the non-immune pony, none of the EHV-
1-infected PBMC showed surface expression of viral antigens (0/18 infected PBMC). 
Cell surface expression of MHC class I molecules was found in 80 to 100 % of the
EHV-1-infected PBMC in the immune ponies (4/5, 4/4, 4/4 and 6/6 infected PBMC in
pony A, B, C and D, respectively) as well as in 88 % of the EHV-1-infected PBMC in the
non-immune pony (15/17 infected PBMC). This resembled the percentage of MHC class
I-positive cells found in non-infected PBMC (83 to 100 %). Figure 4.2.1 (see page 111)
presents a confocal image of 2 non-infected and 1 EHV-1-infected PBMC showing MHC
class I expression.
Serological response to experimental inoculation
The complement-dependent SN titres are shown in Table 3. For the immune ponies,
a clear seroconversion was observed 7 days after experimental inoculation, confirming
their immune-positive status. In the non-immune pony E, antibodies were first detected at
14 d pi.
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Table 3.  Serological response in ponies following experimental inoculation with
EHV-1
Complement-dependent SN titre at … d piPony Status at
inoculation
SN (IPMA)
titre at
inoculation 0 7 14 21 28
A immune 48 48 96 256 ≥ 384 256
B immune 32 32 96 ≥ 384 ≥ 384 ≥ 384
C immune 4 4 24 192 192 128
D immune < 2 (10) < 2 48 ≥ 384 256 256
E non-immune < 2 (< 10) < 2 < 2 32 ≥ 384 ≥ 384
4.2.5 Discussion
The inability of the currently available vaccines to provide a full protection against
EHV-1 has serious economic implications and stimulated the search for alternative
vaccination approaches (reviewed by van Maanen, 2002). So far, relatively little research
has been performed on the actual mechanism that enables EHV-1 to circumvent
recognition and destruction by the immune system of the horse. The present in vivo study
demonstrates that the vast majority of EHV-1-infected PBMC present in the blood during
viremia in experimentally inoculated horses lacks visually detectable levels of viral
antigens on their cell surface. Absence of viral antigen expression on the surface of EHV-
1-infected PBMC during viremia represents a potential strategy for the infected cells to
circumvent the antibody-mediated immune response in the horse.
Besides via the antibody-mediated immune response, virus-infected cells can be
recognized and destroyed via the cell-mediated immune response as well. O’Neill et al.
(1999) already demonstrated high frequencies of EHV-1-specific, genetically restricted
CTL presursors after multiple experimental inoculation of ponies. Breathnach (2001)
found that CTL are elicited by experimental infection of horses with EHV-1.
Notwithstanding the presence of high frequencies of EHV-1-specific CTL, infected
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PBMC can be detected in the blood circulation of horses upon challenge, suggesting that
their recognition by CTL is impaired (O’Neill et al., 1999). The results from the present
study show that the impaired recognition is not arising from an absence of MHC class I
molecules on the surface of EHV-1-infected PBMC, since 80 to 100 % of the infected
PBMC showed surface expression of MHC class I molecules. From our study, it cannot
be concluded whether the MHC class I molecules are effectively presenting EHV-1
peptides. Inhibition of viral peptide supply to MHC class I may act as another potential
strategy to avoid recognition of infected cells by CTL (reviewed by Favoreel et al.,
2000). Also, mechanisms of herpesvirus-induced inhibition of CTL activity independent
on MHC class I may be responsible for impaired recognition of infected cells. This was
already described for Epstein-Barr virus, which encodes an interleukin-10 homologue,
BCRF1. BCRF1 exhibits a variety of effects on the T-helper cell type response, resulting
in down-regulation of CTL activity (Hsu et al., 1990; Vieira et al., 1991). A similar
interleukin-10 homologue, E7, is encoded by EHV-2 (Telford et al., 1994).
Our results, together with those of O’Neill et al. (1999) and Breathnach (2001),
indicate that EHV-1 infection not only induces a normal antibody response but also a
normal cell-mediated immune response. This emphasizes that immune escape of EHV-1
during viremia is not the effect of an impaired response of the immune system but rather
a gain of the virus that can hide itself from recognition by the immune system. In this
perspective, it will be very difficult to design a vaccine that can fully prevent EHV-1-
infected PBMC to spread to internal organs and to induce abortion or nervous system
disorders. Therefore, one may suggest that future approaches to prevent EHV-1-
associated disease should focus on improving vaccines that induce local immunity in
such a way that replication of EHV-1 in the respiratory tract and subsequent viremia are
prevented. Even though such vaccines may be sufficient to prevent re-infection, they will
not be helpful to prevent reactivation of latent EHV-1 from PBMC.
The total number of infected PBMC was rather low in the present study when
compared to the studies of Scott et al. (1983) and Gibson et al. (1992). This may be due
to a difference in virulence between the EHV-1 strains used. Mumford et al. (1994)
already demonstrated that the number of infected leukocytes varies depending on the
EHV-1 strain. In their study, the maximum number of infected leukocytes was 25-fold
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higher following an infection with the highly virulent EHV-1 strain Ab4, than following
an infection with the less virulent strain V592/2.
The percentages of infected PBMC showing cell surface expression of viral antigens
are somewhat different between the present in vivo study and an earlier in vitro study. In
vitro, 37 % of the EHV-1-infected PBMC showed expression of viral antigens on their
surface (van der Meulen et al., 2003). In vivo, surface expression was found in only 1
infected PBMC in immune ponies and in none of the infected PBMC in the non-immune
pony. It is not likely that infected PBMC showing cell surface expression are selectively
destroyed in vivo by means of EHV-1-specific antibody-mediated immune responses,
since the non-immune pony E lacked infected PBMC with surface expression as well
even though no EHV-1-specific antibodies were present in its blood circulation.
Destruction of PBMC showing surface expression via innate immune responses, like the
antibody-independent, complement-mediated pathway, may be a more reliable
explanation for the low percentage of EHV-1-infected PBMC showing cell surface
expression in vivo. Previous studies already demonstrated that the antibody-independent,
complement-mediated pathway can vouch for the destruction of approximately 10 % of
EHV-1-infected PBMC showing surface expression in vitro within 1 hour of exposure to
20 % unheated equine serum (van der Meulen et al., 2003). Besides this, it cannot be
excluded that cell surface expression of viral antigens is absent on a higher number of
cells in vivo, because of so far unknown viral and/or cellular factors influencing the
process of surface expression.
We can conclude from the present study that, by far, the most EHV-1-infected
PBMC lack viral antigen expression on their cell surface during viremia, thereby enabling
these cells to avoid recognition and destruction by the antibody-mediated immune
response. The percentage of infected PBMC showing surface expression of MHC class I
molecules during viremia was 80 to 100 % and, therefore, absence of cell surface
expression of MHC class I molecules will not account for the inefficient recognition of
EHV-1-infected PBMC by CTL.
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Figure 3.2.1.  Formation of clusters of equine PBMC, induced by stimulation with
IONO/PDB, facilitates cell-to-cell transmission of EHV-1
PBMC were stimulated during 24 hours with IONO/PDB and infected afterwards. At 8, 17 and 24 h pi an
immunofluorescence staining using biotinylated horse anti-EHV-1 polyclonal antibodies and streptavidine-
Texas Red‚ was performed to detect viral antigen-positive cells. Clusters of PBMC are shown in Figure (a)
as detected by light microscopy. Bar, 10 µm. Figures (b), (c) and (d) show the 3-dimensional images of a
cluster containing 1, 2 and three adjacent infected cells, respectively, constructed by super-imposing the
images obtained at 20 different sections throughout the cell by confocal microscopy. Bar, 5 µm.
Figure 3.2.2.  Close intercellular contacts are present between adjacent infected
PBMC
Figures (a) and (b) show a single section throughout the infected cells in the clusters shown in Figure 1 (c)
and (d), respectively. Bar, 5 µm.
(b)(a)
(a)
(c) (d)
 
(b)
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Figure 4.1.1.  Expression patterns of viral antigens on the cell surface of EHV-1-
infected PBMC
PBMC were stimulated during 24 hours with ionomycin/phorbol dibutyrate and infected afterwards. At 6,
9, 12 and 24 h pi, cells were fixed and an immunofluorescence staining was performed using FITC-labeled
horse anti-EHV-1 IgG to detect cell surface expression of viral antigens and, after permeabilisation,
biotinylated horse anti-EHV-1 IgG and streptavidin-Alexa Fluor® 350 to determine whether a cell was
infected. Figures (a), (b) and (c) represent confocal images of an EHV-1-infected PBMC without surface
expression, with expression on part of the cell surface (‘focal expression’), and with expression on the
entire cell surface (‘general expression’), respectively. Bar 5 mm.
(a) (b) (c)
(a) (b)
Figure 4.1.2.  Absence of cell surface
expression protects EHV-1-infected PBMC
from complement-mediated cell lysis
PBMC were stimulated during 24 hours with
ionomycin/phorbol dibutyrate and infected afterwards.
At 24 h pi, a complement-mediated cell lysis assay was
performed. Cells were successively incubated with
protein G-purified and FITC-labeled horse anti-EHV-1
IgG (green), with non-inactivated EHV-1-negative
horse serum as a source of complement and with
ethidium monoazide bromide to determine the viability
of the cells (red). After fixation and permeabilisation,
biotinylated horse anti-EHV-1 IgG and streptavidin-
Alexa Fluor® 350 were added to determine whether a
cell was infected (blue). Pictures (a) and (b) are
confocal images of a lysed, EHV-1-infected PBMC
showing general cell surface expression and of a
viable, EHV-1-infected PBMC without cell surface
expression, respectively. Bar 5 mm.
Figure 4.2.1.  MHC class I is
expressed on the surface of EHV-1-
infected PBMC
PBMC were isolated from a pony
experimentally inoculated with EHV-1. After
fixation, cells were incubated with PT85A, a
monoclonal mouse anti-MHC class I
antibody, followed by goat anti-mouse-FITC
(green). After subsequent permeabilisation,
cells were incubated with biotinylayed horse
anti-EHV-1 IgG followed by streptavidin-
Texas Red‚ (red). The picture shows a
confocal image 2 non-infected PBMC (full
arrow) and 1 EHV-1-infected (dashed arrow)
PBMC showing a clear surface expression of
MHC class I. Bar 5 mm.
(a) (b)
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GENERAL DISCUSSION
The first purpose of the studies described in this thesis was to closely examine the
replication kinetics of equine herpesvirus 1 (EHV-1) and to identify the infected cells in
freshly isolated as well as in mitogen-stimulated peripheral blood mononuclear cells
(PBMC) in vitro. It was found that monocytes as well as T- and B-lymphocytes were
susceptible to EHV-1 infection. The susceptibility of freshly isolated lymphocytes to
EHV-1 was extremely low, but increased by stimulation of the cells with mitogens. Our
finding that freshly isolated lymphocytes were highly refractory to EHV-1 infection in
vitro is not fully in agreement with earlier findings in PBMC from experimentally
inoculated ponies (Scott et al., 1983). Scott et al. (1983) found that during viremia, T-
lymphocytes were the predominant cell type that harboured virus even before culturing
with mitogens in vitro. The disparity between the results of Scott et al. and our results
may be explained as follows. It is known that an experimental EHV-1 infection of ponies
results in an increase in the percentage of circulating blastic cells up to 40 % during
viremia (McCulloch et al., 1993). It is very well possible that the PBMC collected by
Scott et al. (1983) had already undergone blastic transformation in the ponies as a
consequence of infection, thereby replacing the effect of mitogen stimulation in vitro.
We, on the other hand, collected PBMC from healthy horses which were likely to contain
almost no blastic cells prior to mitogen stimulation, giving a probable explanation for the
very low susceptibility of lymphocytes to EHV-1 in the freshly isolated samples.
Our in vitro studies demonstrated that the influence of mitogen stimulation on the
susceptibility of PBMC to EHV-1 was 2-fold. First, stimulation initiated the entry of a
limited number of lymphocytes into the cell cycle thereby enabling EHV-1 infection of
these cells and, second, mitogens induced the formation of close intercellular contacts
between PBMC thereby facilitating the cell-to-cell transmission of EHV-1. The positive
role of the cell cycle on EHV-1 replication is most likely attributed to proliferation events
active from late G1 onward, since an increase in the percentage of EHV-1-infected
PBMC was highly correlated with an increase in the percentage of cells in the S-phase of
the cell cycle. It seems rather surprising that EHV-1 benefits from factors active during
the cell cycle, knowing that herpesviruses themselves contain a large array of genes,
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which encode viral DNA-metabolizing enzymes. Nevertheless, the replication of several
other herpesviruses depends on these factors as well. For example, herpes simplex virus 1
(HSV-1) replication requires the cyclin-dependent kinases 1, 2 or 7 which are involved in
DNA transcription and synthesis while passing through the S-phase of the cell cycle
(Schang et al., 1998, 1999, 2000, 2002). Also, the replication of HSV-2 (Schang et al.,
1998), human cytomegalovirus (HCMV) (Bresnahan et al., 1997) and varicella-zoster
virus (VZV) (Taylor et al., 2001) seems to benefit from cellular cyclin-dependent
kinases, since blocking the activity of these kinases results in an inhibition of viral
replication. Upon experimental EHV-1 infection of ponies, McCulloch et al. (1993)
demonstrated an increase in the percentage of circulating blastic cells from 10 up to 40 %
during viremia. Whether EHV-1 benefits from these proliferation events in PBMC in vivo
remains unclear.
Beside via activation of specific cell cycle events, mitogens also influenced the
replication of EHV-1 via the formation of clusters of PBMC. Mitogen stimulation
induces the surface expression of several families of cell adhesion molecules, resulting in
a cascade of binding events which lead to the formation of aggregates or clusters of
PBMC (reviewed by Hogg and Landis, 1993). We found that the close intercellular
contacts formed between PBMC within these clusters facilitated the transmission of
EHV-1 from infected cells to uninfected, adjacent cells. Addition of virus-neutralizing
antibodies in the medium during infection did not affect this transmission of EHV-1,
proving that it occurred via direct cell-to-cell spread (van der Meulen et al., 2002). Our
findings that direct cell-associated transmission of EHV-1 is facilitated as a result of close
intercellular contacts initiated by cell adhesion molecules together with the knowledge
that adherence of equine leukocytes to equine endothelial cells requires the expression of
certain adhesion molecules (Smith et al., 2002) may suggest that adhesion molecules play
a role in the transfer of virus from infected circulating PBMC to endothelial cells of the
target organs, such as the pregnant uterus and the nervous system.
From the studies presented in this thesis, it was concluded that, in freshly isolated
PBMC, monocytes are the most important cell fraction in which EHV-1 replicates. Our
studies also allowed to conclude that lymphocytes become more susceptible following
stimulation with mitogens because of the initiation of certain proliferation events in
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stimulated cells and because of the facilitated cell-associated transmission of EHV-1
within stimulated cell clusters.
The second purpose of the studies described in the present thesis was to obtain more
insights in the mechanism by which EHV-1-infected PBMC are able to circulate in the
immune horse without efficiently being eliminated by the host’s immune system. From
our in vitro studies, it became clear that EHV-1-infected PBMC were able to express viral
antigens on their cell surface, as described in Chapter 3.1. However, the PBMC that
showed cell surface expression of viral antigens only represented one-third of all EHV-1-
infected PBMC, as demonstrated by the studies described in Chapter 4.1. The remaining
two-thirds lacked visually detectable levels of EHV-1 antigens on their cell surface. Since
absence of EHV-1 antigens on the surface may prevent the binding of virus-specific
antibodies to the infected cell, we hypothesized that PBMC without surface expression
remain unrecognizable for the antibody-dependent components of the immune system.
Indeed, it was demonstrated in our in vitro studies that infected PBMC without viral
antigens on their surface, were insensitive to antibody-dependent, complement-mediated
cell lysis and, most likely, to antibody-dependent, cell-mediated cytotoxicity as well.
Focal surface expression rendered infected PBMC much less susceptible to antibody-
dependent lysis in comparison to infected PBMC showing generalized surface
expression. From these results, we concluded that absence of viral antigens on the cell
surface, either partial or complete, represents a potential strategy of herpesvirus-infected
PBMC to avoid antibody-dependent lysis, in addition to the strategies already described
in Chapter 1.4.1 of the present thesis.
Amongst all EHV-1-infected PBMC in vitro, approximately 10 % showed a
generalized expression of viral antigens on their surface. It is striking that despite the
extensive presence of viral antigens on their surface, 70 % of these cells survived in the
presence of antibody and complement. Two likely explanations may be put forward.
First, the generally low efficiency of equine complement, as described by Ish et al.
(1993), may have accounted for the high number of surviving cells showing generalized
surface expression. Second, it is possible that certain EHV-1 glycoproteins expressed on
the cell surface interfered with the activation of the complement cascade by displaying Fc
receptor activity. For suid herpesvirus 1 (SuHV-1) (Favoreel et al., 1999b) and varicella-
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zoster virus (VZV) (Litwin et al., 1992), the glycoprotein complex gE/gI has been shown
to possess such Fc receptor activity and expression of these glycoproteins has already
been demonstrated on porcine blood monocytes (Favoreel et al., 2000) and human PBMC
(Mainka et al., 1998). Moreover, Van de Walle et al. (in press) confirmed that expression
of gE/gI on SuHV-1-infected monocytes helps to avoid efficient antibody-dependent,
complement-mediated lysis. Homologues of gE and gI are also expressed by EHV-1
(Audonnet et al., 1990; Elton et al., 1991; Telford et al., 1992), but it remains the subject
of future investigation to determine whether they possess Fc receptor activity.
We extended our studies to experimentally inoculated ponies to determine whether
absence of viral antigens on the cell surface, as observed in vitro, also arises in EHV-1-
infected PBMC during viremia. It was clearly demonstrated that lack of viral antigen
expression on the surface of infected PBMC also occurred during the viremic phase of an
acute EHV-1 infection, emphasizing the relevance of this potential strategy to avoid
antibody-mediated lysis. However, infected PBMC may not only be destroyed via
antibody-mediated lysis, but also via major histocompatibility complex (MHC) class I-
dependent, cytotoxic T-lymphocyte (CTL)-mediated lysis. That this CTL response, like
the antibody-dependent response, is not fully capable of eliminating EHV-1-infected
PBMC in the horse is illustrated by the study of O’Neill et al. (1999). They demonstrated
the presence of viremia in ponies despite high frequencies of EHV-1-specific CTL
precursors which have the potency to kill EHV-1-infected cells. In the present studies, we
examined whether absence of MHC class I molecules on the surface of EHV-1-infected
PBMC could be responsible for inefficient elimination of the cells by CTL during viremia
in experimentally inoculated ponies. It was found that 80 to 100 % of the EHV-1-infected
PBMC showed surface expression of MHC class I molecules, which was similar as
observed in non-infected PBMC. Therefore, we concluded that the impaired elimination
of circulating infected PBMC by CTL during an EHV-1 infection in the horse does not
arise from the absence of MHC class I molecules on the cell surface.
Lack of viral antigens on the surface of EHV-1-infected PBMC during viremia was
observed independently of the immune status of the ponies, indicating that not the
components of the immune system but the virus itself or virus - cell interactions  are
responsible for the lack of surface expression. This is different from the clearance of viral
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antigens from the surface of SuHV-1-infected monocytes, which results from an
antibody-dependent endocytosis (Favoreel et al., 1999a). As already mentioned while
describing the replication cycle of EHV-1 (Chapter 1.2.1), viral proteins are co-
translationally transported into the endoplasmatic reticulum (ER) and, subsequently,
transported via the Golgi apparatus to the cell surface. For VZV (Wang et al., 1998) and
SuHV-1 (Favoreel, personal communication), which show a very similar replication
cycle as EHV-1, it was found that certain glycoproteins play an important role in this
transport process. For example, expression of the VZV glycoproteins gE and gI is
necessary for the other VZV glycoproteins gB, gC, gH and gL to reach the trans-Golgi
network suggesting that gE and gI serve as “navigators” that guide the other
glycoproteins to the trans-Golgi network (Wang et al., 1998). For SuHV-1, it was
demonstrated that cells infected with a gE-/gI- mutant displayed a reduced surface
expression of gB suggesting that the gE/gI complex has a navigating role for at least
some of the other viral glycoproteins in SuHV-1-infected cells (Favoreel, personal
communication). We hypothesize that the cell surface expression in EHV-1-infected
PBMC may also be mediated by one or more viral glycoprotein(s) that serve(s) as a
“navigator” for all viral glycoproteins and, consequently, we suggest that absence of all
viral glycoproteins on the cell surface may be the result of an impaired or even absent
expression of that(those) glycoprotein(s) in the infected cell. Preliminary experiments
carried out in our laboratory indicated that EHV-1 glycoprotein gC may be such a
“navigator” protein. It was found that approximately two-thirds of the EHV-1-infected
PBMC completely lacked expression of gC at 24 hours after inoculation, which is similar
to the number of infected PBMC that lack expression of all glycoproteins on their cell
surface at that time.
Even though absent surface expression of viral antigens on EHV-1-infected PBMC,
as observed in our studies, may help in avoiding antibody-mediated lysis and even though
other, yet unknown, strategies may help in avoiding CTL-mediated lysis, it is clear that a
natural EHV-1 infection is able to induce a short-lived protective immune response
against EHV-1-induced viremia. Indeed, horses do not develop viremia upon re-infection
within 5 months after a previous EHV-1 infection despite the occurrence of viral
replication in the respiratory tract (Edington et al., 1990; Gibson et al., 1992; Slater et al.,
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1993; Tewari et al., 1993). Also, challenge experiments performed in 2 immune ponies at
our laboratory showed that at least 1 animal was still protected against viremia at 6
months after a previous infection (van der Meulen, unpublished results). EHV-1 re-
infection at later time points following prior infection may induce viremia, but our in vivo
study demonstrated that the number of circulating EHV-1-infected PBMC in the
infection-immune ponies following challenge was 1.5- to 20-fold lower when compared
to that in the non-immune pony. The relevance of the latter finding in view of protection
against EHV-1-induced abortion or neurological disease remains to be confirmed, but it is
logical to suggest that a reduction in the number of infected PBMC reduces the chance of
interaction with endothelial cells of the target organs and, consequently, decreases the
chance for EHV-1-induced abortion or neurological disease.
In contrast to the immunity evoked by natural EHV-1 infection, the immunity
induced by vaccines which are commercially available for the prevention of EHV-1-
induced abortion, is much less efficient to protect against EHV-1-induced viremia upon
challenge (Burrows et al., 1984; Bürki et al., 1990; Heldens et al., 2001). To find out
which immunological factors are of key importance in determining the degree of viremia
remains the subject for future research. We believe that the inability of EHV-1 to induce
viremia is the result of an efficient local immune response that minimizes virus
replication in the respiratory epithelia and, importantly, reduces invasion of the virus into
the deeper tissues, thereby preventing EHV-1 from reaching the draining lymph nodes
and the blood circulation. Whereas replication of wild type virus in the respiratory tract
may be sufficient to induce such a local immune response, the restricted replication of the
attenuated EHV-1 vaccine strains or the lack of replication of the inactivated EHV-1
vaccine strains in the respiratory tract may, in turn, be insufficient to induce such a local
immune response.
 The knowledge that the immunity induced by a natural infection is capable of
protecting against EHV-1-induced viremia for at least 5 months after primary infection
holds a promising message. Apparently, the immunity evoked by EHV-1 can prevent
viremia for a short period of time, which strongly suggests that EHV-1-induced abortion
and nervous system disorders may also be prevented. For future vaccine development, it
seems indispensable to find out what components of the immune system achieve this
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protective response against EHV-1-induced viremia. Efforts should be put in the
development of vaccines that induce a strong local immunity. In this manner, replication
of EHV-1 in the epithelium of the respiratory tract may be hindered and, subsequently,
viremia may be prevented.
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6.1 SUMMARY
Equine herpesvirus 1 (EHV-1) is recognized worldwide as a major pathogen of
horses causing serious economic losses due to abortion, neonatal foal death and, less
frequently, nervous system disorders. Peripheral blood mononuclear cells (PBMC) play a
key role in the pathogenesis of an EHV-1 infection, both in naive and in immune horses,
transporting EHV-1 from the primary site of replication to the target organs such as the
pregnant uterus and the nervous system.
In Chapter 1, the current knowledge on the characteristics of EHV-1 and on the
interaction of EHV-1 with its host cell as well as with the naive and the immune horse
were reviewed, with emphasis on the role of infected PBMC. Furthermore, the different
strategies that are exploited by herpesviruses to circumvent elimination of infected
PBMC by the immune system of the host were described.
In Chapter 2, the aims of the studies described in the present thesis were put forward.
Our first aim was to obtain more detailed information on the kinetics of EHV-1
replication and on the identity of the infected cells in freshly isolated PBMC as well as in
mitogen-stimulated PBMC. Subsequently, we wanted to unravel the effect of mitogens on
the susceptibility of PBMC to EHV-1. Our second aim was to obtain some insights in
how EHV-1-infected PBMC are able to avoid efficient elimination by humoral and
cellular components of the host’s immune system. Studies were performed using in vitro
infected PBMC as well as infected PBMC isolated from experimentally inoculated
ponies.
The first aim was addressed in Chapter 3:
In Chapter 3.1, a detailed study was performed on the replication of EHV-1 in
freshly isolated, equine PBMC and the effect of mitogen stimulation on the replication
kinetics of EHV-1 was investigated. Therefore, cytoplasmic and plasma membrane
expression of viral antigens, intra- and extracellular virus titres and plaque formation in
co-culture were determined in a population of freshly isolated and of mitogen-stimulated
PBMC following inoculation with the Belgian EHV-1 strain 97P70. EHV-1 replicated in
freshly isolated monocytes, although in a highly restricted way. Viral antigens were
found in a maximum number of 8.7 % of the monocytes at 12 hours post inoculation (h
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pi). The infection was productive in only 0.16 % of the monocytes, with a virus yield of
100.7 tissue culture infectious dose 50 (TCID50) per productive cell. In a population of
resting lymphocytes, 0.9 % of the cells were infected and less than 0.05 % produced
infectious virus. The virus yield was 100.1 TCID50 per productive cell. However, after
prestimulation with different mitogens, the number of EHV-1-infected lymphocytes
increased 4 to 12 times. The susceptible lymphocytes were T-lymphocytes. No infected
B-lymphocytes were detected due to a loss of these cells during subsequent stimulation,
inoculation and incubation. In mitogen-stimulated PBMC, a clear expression of viral
antigens was found on the plasma membrane of 8 % of all cells. In conclusion, it can be
stated that in freshly isolated PBMC, monocytes are the most important cell fraction in
which EHV-1 replicates. After mitogen stimulation of the PBMC, T-lymphocytes
become more susceptible.
In the first part of Chapter 3.2, the identity of the EHV-1-infected, mitogen-
stimulated PBMC was examined more thoroughly. It was found that among the viral
antigen-positive PBMC, 38.4 ± 4.5 % were CD5+ T-lymphocytes (18.1 ± 3.2 % CD4+;
13.6 ± 1.8 % CD8+), 18.1 ± 5.4 % were B-lymphocytes, 8.5 ± 3.9 % were monocytes and
35 % remained unidentified. This composition of EHV-1-infected PBMC reflected well
the composition of the total population of PBMC. In the second part of Chapter 3.2, the
mechanism(s) by which mitogen stimulation affected the susceptibility of PBMC to
EHV-1 were characterized. The role of the cell cycle in the increased susceptibility to
EHV-1 upon stimulation was examined by stimulating PBMC during 0, 12, 24 and 36
hours prior to inoculation. A high correlation was found between the increase of cells in
the S- (r = 0.974) and G2/M-phase (r = 0.927) at the moment of inoculation and the
increase of infected cells at 12 h pi. This suggests that a specific stage of the S-phase or
S- and G2/M-phase facilitates viral replication. At 24 h pi, lower correlations were found
suggesting that other effects are involved. From 12 hours after addition of ionomycin/
phorbol dibutyrate (IONO/PDB), formation of clusters or aggregates of PBMC became
manifest. It was examined if close intercellular contacts in these clusters facilitated cell-
to-cell transmission of EHV-1. Between 8 and 17 h pi, the percentage of clusters
containing adjacent infected cells increased from 1.6 to 13.4 % and the maximal number
of adjacent infected cells increased from 2 to 4. Confocal microscopy visualized close
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intercellular contacts between adjacent infected cells. It can be concluded that mitogen
stimulation positively influences an EHV-1 infection in 2 ways: (i) by initiating specific
cell cycle events and (ii) by inducing the formation of clusters of PBMC, thereby
facilitating transmission of EHV-1 from infected cells to uninfected adjacent cells.
The second aim of the studies described in the present thesis was addressed in
Chapter 4:
In Chapter 4.1, an in vitro study was performed to investigate how EHV-1-infected
PBMC are able to avoid elimination by the antibody-dependent immune responses. It was
found that the majority of EHV-1-infected PBMC (approximately 70 %) lacked
expression of viral antigens on their surface. Absence of surface expression was observed
independently of the subtype of PBMC. Among the remaining 30 % of the infected
PBMC that did express viral antigens on their surface, two-thirds expressed antigens on
part of the cell surface only, a status designated ‘focal expression’, and one-third
expressed EHV-1 antigens on the entire surface, a status designated ‘general expression’.
When EHV-1-inoculated PBMC were incubated in the presence of antibody and of serum
as a source of complement, it was found that between 1.2 and 3.6 % of the infected
PBMC without cell surface expression were lysed. This percentage was similar as
observed for non-infected PBMC suggesting that the PBMC without cell surface
expression are insensitive to complement-mediated lysis. In contrast, for infected PBMC
showing general surface expression, between 19.4 and 31.2 % of the cells were lysed in
the presence of antibody and complement, which was significantly higher when
compared to non-infected PBMC. When complement was added in the absence of
antibodies, 10.5 % of PBMC showing general surface expression were lysed, whereas
addition of antibodies in the absence of complement resulted in 5.4 % lysed cells. PBMC
showing general surface expression are apparently destroyed by three different immune
mechanisms. Binding of antibodies to the surface of these infected PBMC in the absence
of complement triggered destruction most likely via antibody-dependent, cell-mediated
cytotoxicity (natural killer (NK) cells and phagocytes). Lysis by complement in the
absence of antibodies most likely occurred via the antibody-independent, complement-
mediated pathway, whereas addition of antibodies increased the percentage of lysed cells
by activation of the antibody-dependent, complement-mediated pathway. For infected
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PBMC showing focal surface expression, the percentage of lysed cells was only
significantly higher compared to non-infected PBMC when an antibody concentration of
1.6 mg/ml and a serum concentration of 20 % were used (8.3 % lysed cells). In summary,
at least two-thirds of EHV-1-infected PBMC lack cell surface expression of viral
antigens. Absence of surface expression was observed independently of the subtype of
PBMC. It protects infected PBMC from antibody-dependent and antibody-independent
lysis by equine complement and may, therefore, represent a potential strategy of immune
evasion.
Based on the findings of the in vitro study, it was examined in Chapter 4.2 whether
EHV-1-infected PBMC also lacked surface expression of viral antigens during viremia
upon experimental inoculation of immune ponies. Moreover, surface expression of major
histocompatibility complex (MHC) class I molecules was examined on infected PBMC,
since MHC class I molecules present viral peptides to cytotoxic T-lymphocytes (CTL)
and thus also play a role in making infected cells recognizable for the immune system.
Four infection-immune ponies and 1 EHV-1-negative control pony were inoculated with
the Belgian EHV-1 strain 97P70. PBMC were collected at various time points between 0
and 28 days post inoculation (d pi). Surface expression of viral antigens and MHC class I
molecules on EHV-1-infected PBMC was determined by immunofluorescence labeling.
For the immune ponies, expression of viral antigens on the surface of EHV-1-infected
PBMC was only observed in 1 pony in 1 out of 8 examined EHV-1-infected PBMC (14 d
pi). In the other three immune ponies, all examined EHV-1-infected PBMC lacked
visually detectable levels of plasma membrane-anchored viral antigens (0/7, 0/8 and 0/8
infected PBMC, respectively). Also in the non-immune control pony, none of the EHV-1-
infected PBMC showed surface expression of viral antigens (0/18 infected PBMC). Cell
surface expression of MHC class I molecules was found in 80 to 100 % of the EHV-1-
infected PBMC in the immune ponies as well as in 88 % of the EHV-1-infected PBMC in
the non-immune pony. This resembled the percentage of MHC class I-positive cells
found in non-infected PBMC (83 to 100 %). We concluded from the in vivo study that, by
far, the most EHV-1-infected PBMC lack viral antigen expression on their cell surface
during viremia, thereby enabling these cells to avoid recognition and destruction by the
antibody-mediated immune response. The percentage of EHV-1-infected PBMC showing
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surface expression of MHC class I during viremia was 80 to 100 %. Therefore, absence
of cell surface expression of MHC class I molecules will not account for the inefficient
recognition of EHV-1-infected PBMC by CTL.
Following general conclusions can be made from the studies performed in the
present thesis:
(1) T-lymphocytes, B-lymphocytes and monocytes are susceptible to EHV-1
infection. Lymphocytes become more susceptible following stimulation with
mitogens because of the initiation of certain proliferation events in stimulated
cells and the facilitated cell-associated transmission of EHV-1 within stimulated
cell clusters.
(2) Absence of viral antigens on the cell surface, either partial or complete, represents
a potential strategy of herpesvirus-infected PBMC to avoid antibody-dependent
lysis.
(3) The impaired elimination of circulating infected PBMC by CTL during an EHV-1
infection in the horse does not arise from an absence of MHC class I molecules on
the cell surface.
(4) The number of circulating EHV-1-infected PBMC in the infection-immune ponies
following challenge is reduced when compared to that in the non-immune pony. It
is logical to suggest that a reduction in the number of infected PBMC during
viremia reduces the chance of their interaction with endothelial cells of the target
organs and, consequently, reduces the incidence of EHV-1-induced abortion or
neurological disease.
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6.2 SAMENVATTING
Het equine herpesvirus 1 (EHV-1) is een belangrijk pathogeen voor paarden.
Wereldwijd veroorzaken EHV-1-geïnduceerde uitbraken van abortus, neonatale sterfte
en, in mindere mate, zenuwstoornissen voor grote economische verliezen. Perifere bloed
mononucleaire cellen (PBMC) spelen een sleutelrol in de pathogenese van een EHV-1
infectie, zowel in naïeve paarden als in immune paarden. Ze vervoeren het virus van de
plaats van primaire vermeerdering naar de doelwitorganen zoals de drachtige baarmoeder
en het zenuwstelsel.
In hoofdstuk 1 werd een overzicht gegeven van de huidige kennis over het EHV-1,
over zijn interactie met de gastheercel en over zijn interactie met het naïeve en het
immune paard. Er werd hierbij vooral aandacht besteed aan de rol van de PBMC.
Daarnaast werden de verschillende immuno-evasieve mechanismen besproken die
herpesvirus-geïnfecteerde PBMC in staat stellen om te ontsnappen aan de antistof-
afhankelijke en de cel-afhankelijke immuunreacties van de gastheer.
In hoofdstuk 2 van deze thesis werden de doelstellingen van de verschillende studies
uiteengezet. Een eerste doelstelling bestond er uit om de kinetiek van vermeerdering van
EHV-1 te bestuderen en om de identiteit van geïnfecteerde cellen te bepalen, enerzijds in
een populatie van vers geïsoleerde PBMC en anderzijds in een populatie van PBMC
gestimuleerd met mitogenen. Bijkomend wilden we nagaan wat het effect is van
mitogene stimulatie op de gevoeligheid van PBMC voor een EHV-1 infectie. De tweede
doelstelling bestond er uit om enkele inzichten te verwerven in de wijze waarop EHV-1-
geïnfecteerde PBMC hun uitschakeling door antistof- en major histocompatibility
complex (MHC) klasse I-afhankelijke immuunreacties kunnen ontlopen. Dit werd
onderzocht aan de hand van in vitro-geïnfecteerde PBMC en geïnfecteerde PBMC
geïsoleerd uit experimenteel geïnoculeerde pony’s.
In hoofdstuk 3 kwam de eerste doelstelling aan bod:
In hoofdstuk 3.1 werd een gedetailleerde studie uitgevoerd van de
vermeerderingskinetiek van EHV-1 in vers geïsoleerde equine PBMC en in equine
PBMC gestimuleerd met verschillende mitogenen. Diverse parameters werden bestudeerd
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zoals de expressie van virale antigenen in het cytoplasma en op de plasmamembraan,
intracellulair en extracellulair geproduceerde virushoeveelheden en de vorming van
plaques in een co-cultuur van PBMC en konijnenniercellen (RK13). Vermeerdering van
EHV-1 vond plaats in vers geïsoleerde monocyten, zij het in beperkte mate. Virale
antigenen werden teruggevonden in maximum 8,7 % van de monocyten op 12 uren na
inoculatie. Een productieve infectie was slechts aanwezig in 0,16 % van de monocyten en
de virusopbrengst per productief geïnfecteerde cel bedroeg 100,7 weefselcultuur
infectieuze dosis. In een populatie van vers geïsoleerde lymfocyten waren slechts 0,9 %
van de cellen geïnfecteerd en minder dan 0,05 % produceerde infectieus virus. De
virusopbrengst per productief geïnfecteerde lymfocyt bedroeg 100,1 weefselcultuur
infectieuze dosis. Werden de lymfocyten daarentegen gestimuleerd met mitogenen
voorafgaande aan de infectie, dan nam het aantal geïnfecteerde lymfocyten 4 tot 12 maal
toe. De geïnfecteerde cellen in de populatie van gestimuleerde lymfocyten waren vooral
T lymfocyten.  Er werden geen geïnfecteerde B lymfocyten waargenomen, maar dit was
te wijten aan een verlies van B lymfocyten tijdens de achtereenvolgende handelingen van
stimulatie, inoculatie en incubatie. In een populatie van gestimuleerde PBMC konden bij
8 % van de cellen virale antigenen worden aangetoond op de plasmamembraan. Uit deze
eerste studie werd besloten dat vermeerdering van EHV-1 in vers geïsoleerde PBMC
vooral plaatsvindt in de monocyten. Worden de PBMC gestimuleerd met mitogenen
voorafgaande aan de infectie, dan worden de T lymfocyten meer gevoelig voor een EHV-
1 infectie. Over een eventuele toename in de gevoeligheid van de B lymfocyten na
stimulatie kon geen uitspraak gedaan worden.
In het eerste deel van hoofdstuk 3.2 werd de identiteit van de met mitogenen
gestimuleerde en met EHV-1-geïnoculeerde PBMC meer in detail uitgewerkt. De
populatie van geïnfecteerde, gestimuleerde PBMC was als volgt samengesteld: 38,4 ± 4,5
% CD5+ T lymfocyten (18,1 ± 3,2 % CD4+; 13,6 ± 1,8 % CD8+), 18,1 ± 5,4 % B
lymfocyten, 8,5 ±  3,9 % monocyten en 35 % ongeïdentificeerde cellen. Deze
samenstelling van de geïnfecteerde PBMC was zeer gelijkaardig aan de samenstelling
van de totale populatie van PBMC. In het tweede deel van hoofdstuk 3.2 werd getracht te
ontrafelen hoe mitogenen de gevoeligheid van PBMC voor een EHV-1 infectie kunnen
doen toenemen. Eerst werd de rol van de celcyclus bestudeerd door PBMC gedurende
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verschillende tijdsintervallen te stimuleren en vervolgens te infecteren.  Er bleek een zeer
goede correlatie te bestaan tussen de toename van het aantal cellen in de S-fase na
stimulatie en de toename van het aantal geïnfecteerde cellen tussen 0 en 12 uren na
inoculatie (r = 0,974). Ook de toename van het aantal cellen in de G2/M-fase na
stimulatie was nauw gecorreleerd met de toename van het aantal geïnfecteerde cellen
tussen 0 en 12 uren na inoculatie (r = 0,927). Deze bevinding suggereert dat welbepaalde
processen die optreden tijdens de S-fase of de S- en G2/M-fase, de vermeerdering van
EHV-1 in PBMC kunnen bevorderen. Op 24 uren na inoculatie werden lagere correlaties
teruggevonden, wat er op wijst dat ook andere factoren een invloed uitoefenen op de
vermeerdering van EHV-1. Vanaf 12 uren na het toedienen van mitogenen aan PBMC
begonnen de cellen aggregaten of clusters te vormen. Er werd nagegaan of de
intercellulaire contacten tussen PBMC in deze clusters de celgeassocieerde overdracht
van EHV-1 konden vergemakkelijken. Het aantal clusters met aanééngesloten
geïnfecteerde cellen nam toe van 1,6 % op 8 uren tot 13,4 % op 17 uren na inoculatie.
Daarenboven nam het aantal aanééngesloten geïnfecteerde cellen binnen de clusters toe
van maximaal 2 tot maximaal 4. Met behulp van confocale microscopie konden de
nauwe, intercellulaire contacten tussen aanééngesloten geïnfecteerde cellen duidelijk in
beeld gebracht worden. Er werd geconcludeerd dat mitogenen een EHV-1 infectie van
PBMC op 2 manieren beïnvloeden: (i) mitogenen stimuleren het optreden van
welbepaalde processen verbonden aan de celcyclus die op hun beurt de
virusvermeerdering vergemakkelijken en (ii) mitogenen induceren nauwe intercellulaire
contacten tussen PBMC die het celgeassocieerd spreiden van het virus van geïnfecteerde
cellen naar niet-geïnfecteerde aanéénsluitende cellen ten goede komen.
De tweede doelstelling werd nader uitgewerkt in hoofdstuk 4:
In hoofdstuk 4.1 werd een in vitro studie verricht die tot doel had te onderzoeken hoe
EHV-1-geïnfecteerde PBMC kunnen ontkomen aan antistof-afhankelijke
immuunreacties. Er werd gevonden dat de meerderheid van de EHV-1-geïnfecteerde
PBMC (ongeveer 70 %) geen virale antigenen tot expressie brengt op de
plasmamembraan. Dit fenomeen werd zowel bij T lymfocyten, B lymfocyten als
monocyten waargenomen. De resterende 30 % van de EHV-1-geïnfecteerde PBMC
vertoonde wel plasmamembraanexpressie, hetzij op het volledige celoppervlak (10 %),
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hetzij op slechts een deel van het celoppervlak (20 %). Om na te gaan of de afwezigheid
van plasmamembraanexpressie de geïnfecteerde cellen onherkenbaar kan maken voor
antistof-afhankelijke, complement-gemedieerde cellyse, werden EHV-1-geïnoculeerde
PBMC geïncubeerd in de aanwezigheid van EHV-1-specifieke antistoffen en EHV-1-
negatief paardenserum als bron van complement. Het percentage lyse in de populatie van
geïnfecteerde PBMC zonder plasmamembraanexpressie bedroeg nooit meer dan 3,6 %,
onafhankelijk van de gebruikte antistof- en serumconcentraties. Dit percentage was gelijk
aan het percentage lyse gevonden in een populatie van niet-geïnfecteerde PBMC. Een
dergelijke bevinding wijst er op dat geïnfecteerde PBMC zonder
plasmamembraanexpressie niet gevoelig zijn aan complement-gemedieerde cellyse.
Daarentegen werden in de populatie van geïnfecteerde PBMC met volledige
plasmamembraanexpressie 19,4 tot 31,2 % gelyseerde cellen teruggevonden. Werd
paardenserum toegevoegd zonder antistoffen, dan bedroeg het percentage gelyseerde
PBMC met volledige plasmamembraanexpressie nog altijd 10,5 % en toevoeging van
antistoffen zonder paardenserum resulteerde in 5,4 % gelyseerde cellen. Blijkbaar kunnen
PBMC met volledige plasmamembraanexpressie op drie verschillende manieren
vernietigd worden. Binding van antistoffen aan de virale antigenen op de
plasmamembraan in de afwezigheid van complement veroorzaakt waarschijnlijk een
vernietiging van de geïnfecteerde cel door antistof-afhankelijke, celgemedieerde
cytotoxiciteit (door natural killer (NK) cellen en fagocyten). Lyse in de aanwezigheid van
complement maar in de afwezigheid van antistoffen verloopt waarschijnlijk via de
antistof-onafhankelijke complement cascade. Tenslotte zal de gelijktijdige aanwezigheid
van antistoffen èn complement bijkomend resulteren in antistof-afhankelijke,
complement-gemedieerde cellyse. Het percentage lyse in de populatie van geïnfecteerde
PBMC met slechts een gedeeltelijke plasmamembraanexpressie was enkel significant
hoger dan de niet-geïnfecteerde PBMC wanneer 1,6 mg antistof/ml en 20 %
paardenserum werden gebruikt (8,3 % gelyseerde cellen). Samengevat kunnen we stellen
dat tenminste 70 % van de EHV-1-geïnfecteerde PBMC geen virale antigenen tot
expressie brengt op de plasmamembraan. Afwezigheid van plasmamembraanexpressie
beschermt de geïnfecteerde cellen tegen antistof-afhankelijke en antistof-onafhankelijke
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lyse door paardencomplement en vormt daarom een mogelijk immuno-evasief
mechanisme van EHV-1-geïnfecteerde PBMC.
In hoofdstuk 4.2 werd vervolgens nagegaan of afwezigheid van
plasmamembraanexpressie van EHV-1 antigenen op geïnfecteerde PBMC ook voorkomt
tijdens de viremie in experimenteel geïnoculeerde, immune pony’s. Bovendien werd de
expressie van MHC klasse I moleculen op de EHV-1-geïnfecteerde PBMC aanwezig
tijdens de viremie, nader bestudeerd. Immers, ook MHC klasse I moleculen spelen een
belangrijke rol bij de herkenning en vernietiging van geïnfecteerde cellen. Ze presenteren
virale peptiden aan cytotoxische T-lymfocyten (CTL) die op hun beurt de geïnfecteerde
cel lyseren. Afwezigheid van MHC klasse I moleculen zou mede verantwoordelijk
kunnen zijn voor de inefficiënte herkenning van EHV-1-geïnfecteerde PBMC door het
immuunsysteem van het paard. Voor de in vivo studie werden 4 infectie-immune pony’s
en 1 EHV-1-negatieve controle pony geïnoculeerd met het Belgische EHV-1 isolaat
97P70 en vervolgens werden PBMC verzameld tussen 0 en 28 dagen na inoculatie. De
expressie van virale antigenen en MHC klasse I moleculen op de EHV-1-geïnfecteerde
PBMC werd bestudeerd aan de hand van immunofluorescentiekleuringen. Bij de immune
pony’s werd plasmamembraanexpressie van virale antigenen enkel waargenomen bij 1
pony en slechts op 1 van de 8 onderzochte EHV-1-geïnfecteerde PBMC (14 dagen na
inoculatie). Bij de andere 3 immune pony’s vertoonde geen enkele van de onderzochte
EHV-1-geïnfecteerde PBMC zichtbare expressie van virale antigenen op hun
plasmamembraan (0 op 7, 0 op 8 en 0 op 8 geïnfecteerde PBMC respectievelijk). Ook bij
de EHV-1-negatieve controle pony werden geen PBMC met plasmamembraanexpressie
van virale antigenen waargenomen (0 op 18 geïnfecteerde PBMC).
Plasmamembraanexpressie van MHC klasse I was daarentegen aanwezig op 80 tot 100 %
van de EHV-1-geïnfecteerde PBMC bij de immune pony’s en op 88 % van de EHV-1-
geïnfecteerde PBMC bij de EHV-1-negatieve controle pony. Deze percentages waren
gelijkaardig aan de percentages geobserveerd in niet-geïnfecteerde PBMC (83 tot 100 %).
Hieruit kunnen we besluiten dat de overgrote meerderheid van de EHV-1-geïnfecteerde
PBMC aanwezig tijdens de viremie, geen virale antigenen tot expressie brengt op de
plasmamembraan. Aldus hebben deze geïnfecteerde cellen een mogelijke immuno-
evasieve strategie om te ontsnappen aan de antistof-afhankelijke immuunreacties van het
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paard. Het percentage EHV-1-geïnfecteerde PBMC met plasmamembraanexpressie van
MHC klasse I moleculen was 80 tot 100 %. Een inefficiënte herkenning van EHV-1-
geïnfecteerde PBMC door CTL zal dus niet te wijten zijn aan afwezigheid van MHC
klasse I moleculen op de plasmamembraan.
Op basis van de studies uitgevoerd in deze thesis kunnen volgende algemene
conclusies naar voren worden gebracht:
(1) Zowel T lymfocyten, B lymfocyten als monocyten zijn gevoelig voor een infectie
met EHV-1. Lymfocyten worden gevoeliger door voorafgaande stimulatie met
mitogenen als gevolg van het optreden van bepaalde proliferatieprocessen in
gestimuleerde cellen en als gevolg van een vergemakkelijkt celgeassocieerd
spreiden van het virus binnen clusters van gestimuleerde cellen.
(2) Een gehele of gedeeltelijke afwezigheid van virale antigenen op de
plasmamembraan van geïnfecteerde PBMC vormt een mogelijke verklaring
waarom EHV-1-geïnfecteerde PBMC kunnen ontsnappen aan de antistof-
afhankelijke componenten van het immuunsysteem.
(3) De inefficiënte herkenning van circulerende geïnfecteerde PBMC wordt niet
veroorzaakt door een afwezigheid van MHC klasse I moleculen op de
plasmamembraan.
(4) Bij de infectie-immune pony’s is het aantal EHV-1-geïnfecteerde PBMC
aanwezig tijdens de viremie na herinfectie, lager dan dat in de EHV-1-negatieve
pony. Het lijkt logisch dat een reductie in het aantal circulerende geïnfecteerde
PBMC leidt tot een verminderde kans op interactie tussen deze PBMC en de
endotheelcellen van de doelwitorganen en, bijgevolg, tot een verminderd aantal
gevallen van EHV-1-geïnduceerde abortus of zenuwstoornissen.
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Na heel wat maanden van zwoegen en zweten lijkt het eindpunt van mijn doctoraat
in zicht. Er wacht echter nog een belangrijke taak en dat is iedereen bedanken die
geholpen heeft bij het tot stand komen van mijn doctoraatswerk.
Allereerst wil ik mijn beide promotoren bedanken. Hans, ik denk dat jij het best te
omschrijven bent als de perpetuum mobile van de wetenschappelijke ideëen. Jij bent een
onmisbare drijfveer geweest bij het maken van mijn doctoraat. Jouw vele ideëen maken
dat menig jonge doctoraatsstudent, inclusief mijzelf, besmet raakt met het
onderzoeksvirus. Bovendien ben ik dankzij jou nu één van de weinige Nederlanders die
een klein woordje West-Vlaams spreekt. Merci!
Professor Pensaert, u zou ik graag bedanken voor de kennis die u mij de afgelopen
jaren heeft bijgebracht. Uw kritische visie heeft me niet alleen veel geleerd over de
wetenschap. Het heeft mij ook geleerd om de niet-wetenschappelijke wereld eerst goed te
interpreteren vooraleer tot een conclusie te komen.
I would like to thank the members of the accompanying committee, Professor
Mettenleiter from the Federal Research Centre for Virus Diseases of Animals in Insel
Riems in Germany, Professor Thiry from the Faculty of Veterinary Medicine at the
University of Liege as well as Professor Deprez and Professor Ducatelle from the Faculty
of Veterinary Medicine at Ghent University. Thank you all for critically reading the
manuscript and for coming forward with many inventive suggestions to improve my
thesis.
De Universiteit Gent zou ik willen bedanken voor de mogelijkheid die ze mij, en
vele andere Nederlandse studenten, geboden heeft om de studie diergeneeskunde aan te
vangen. Daarnaast wens ik de Universiteit Gent te bedanken voor de jaren na mijn studie
die ik heb kunnen invullen als assistent en die geleid hebben tot het huidige
doctoraatswerk.
Al mijn collega’s wil ik van harte bedanken voor de goede werksfeer en voor de
steun tijdens de wetenschappelijke of persoonlijke ‘ups’ en ‘downs’. Allereerst bedank ik
mijn bureaugenoten. Herman, mijn eerste bureaugenoot, jij bent naast Hans de persoon
die mij heeft binnengeloodst in de wondere wereld der immuno-evasie. Geoffrey, mijn
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tweede en meest duurzame bureaugenoot, we hebben heel wat lief en leed gedeeld en ik
kan niet anders zeggen dan dat ik jou heel erg waardeer. Griet, mijn jongste
bureaugenoot, ik ben blij dat ik nu een ‘paarden’maatje heb. Gerlinde, je bent niet alleen
een fijne collega, maar ook een fijne vriendin. Kristin, bedankt voor alle gezellige thee-
pauzes van de afgelopen maanden. Steven, jouw onstuitbaar enthousiasme voor de
wetenschap is een voorbeeld voor menig doctoraatsstudent. Peter, dank je wel dat ik elke
keer weer opnieuw jouw boek over immunologie heb mogen lenen, ook al staat het
volledig op het internet. Geert, Peter en Nathalie, jullie bedank ik voor de hulp bij het
oplossen van al mijn ‘moleculaire’ problemen. En daarenboven ... bedankt Geert, voor de
vele keren dat je de lamp van de fluorescentiemicroscopen hebt vervangen, omdat ik
weeral niet wist hoe het ook weer in elkaar stak, Peter, voor je aanstekelijk
wetenschappelijk enthousiasme en Nathalie, voor je kritische inbreng bij het klaarstomen
van bepaalde verslagen en publicaties. Kristien, jou wil ik bedanken voor je hulp bij het
opstellen van de practica voor de derde kandidatuur en voor het inspringen bij de practica
wanneer ik even in tijdnood zat. Romeo, thanks for spreading those lovely Eastern
flavours every time you have diner. Chris en Dieter, bedankt voor de vele kleuringen die
jullie hebben uitgevoerd. En ... Chris, voor mij ben je bovenal een luisterend oor op het
laboratorium waar je altijd terecht kan. Chantal, bedankt voor de vele miljoenen witte
bloedcellen die je hebt geïsoleerd uit het paardenbloed en Lieve, voor je geduldige uitleg
over virologische testen. En jullie beiden bedank ik om altijd maar weer opnieuw uit te
leggen hoe men nu een infectiviteitstiter moet bepalen. Dat wil toch moeilijk in mijn
hoofd blijven hangen. Carine, ook jou ben ik veel dank verschuldigd voor alle hulp bij
mijn voorbije experimenten en ik waardeer je hulp en interesse voor ons huidige
serologisch onderzoek. Fernand, bedankt voor je hulp met de ponies. Ik denk dat ze het
net zoveel gewaardeerd hebben als ik. En ook bedankt voor de zorg die je draagt voor de
‘inboedel’ van het laboratorium. Trees, jij hebt er toe bijgedragen dat de vele isolaties van
witte bloedcellen altijd weer tot een goed einde gebracht konden worden door er voor te
zorgen dat er altijd medium en PBS was. Gert, jij verdient een eervolle vermelding als
entertainer die mij altijd wel een (glim)lach kon ontlokken. Liliane, bedankt voor alle
administratieve hulp tijdens de afgelopen jaren. En hetzelfde geldt natuurlijk voor Mieke,
maar dan tijdens de afgelopen weken. Dirk, op jou kon ik altijd rekenen als er weer een
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weerbarstige computer bijgestuurd moest worden. Marijke, bedankt voor de
ontspannende babbeltjes tijdens het kuisen van ons bureau en, bovenal, bedankt dat je het
laboratorium elke dag weer piekfijn in orde te brengt. En tenslotte wil ik alle mensen
bedanken die inmiddels het laboratorium hebben verlaten, want ook zij waren stuk voor
stuk fijne collega’s.
Behalve op mijn werk zijn er ook talrijke mensen daarbuiten die ik wil bedanken.
Omdat het zwaartepunt van het doctoraat niet langer op het wetenschappelijk gedeelte,
maar op het dankwoord zou komen te liggen wanneer ik iedereen persoonlijk ga
bedanken, zal ik mij beperken tot mijn naasten. Papa en mama, jullie wil ik bedanken
voor de onaflatende steun die jullie mij gegeven hebben tijdens de studie
diergeneeskunde, tijdens mijn doctoraat en tijdens alle andere stappen in mijn leven die
genomen zijn of op het punt staan genomen te worden. Peter, bedankt voor de goede
zorgen en bezorgdheden voor je ‘kleine’ zusje. Je bent voor mij altijd een groot voorbeeld
geweest, al denk ik niet dat ik ooit de wereld zal rondtrekken. En oma, ik ben blij dat ik
zoveel op je lijk!
Aleid en Ester, bedankt voor jullie trouwe vriendschap en steun tijdens de studie en
tijdens de afgelopen jaren. Ik hoop dat we alledrie kunnen blijven vechten voor onze
dromen en dat we ze alledrie uiteindelijk kunnen realiseren.
David, jou wil ik bedanken voor je begrip en steun tijdens de afgelopen maanden als
ik weer eens een heel weekend achter de computer verscholen zat, voor de soms
broodnodige dosis relativeringsvermogen als ik dacht dat de wereld enkel nog maar uit
virussen bestond en voor je hulp bij het afwerken van de thesis. Deze thesis is voor mij
een belangrijke mijlpaal in mijn leven. Er zullen echter nog vele andere mijlpalen volgen,
sommige zelfs al zeer binnenkort, en ik kijk er naar uit om ze allemaal samen met jou te
bereiken.
En tenslotte, misschien wat ongebruikelijk, zou ik graag de verschillende trouwe
viervoeters bedanken die toch een onmisbare bijdrage hebben geleverd aan mijn
doctoraat. Bedankt Babette, Kleine, Mieke, paardjes van verloskunde, Zwarte, Vos,
Hengst en Bruine. En bovenal bedankt Smokey, voor de bijdrage aan de wetenschap en
voor de vele aangename borsteluurtjes na het werk.
